Combining Network Pharmacology and Experimental Validation to Demonstrate That Salidroside Alleviates Acute Lung Injury by Inhibiting Ferroptosis via the MAPK/GPX4 Pathway

Combining Network Pharmacology and Experimental Validation to Demonstrate That Salidroside Alleviates Acute Lung Injury by Inhibiting Ferroptosis via the MAPK/GPX4 Pathway | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Combining Network Pharmacology and Experimental Validation to Demonstrate That Salidroside Alleviates Acute Lung Injury by Inhibiting Ferroptosis via the MAPK/GPX4 Pathway Min Zhao, Wei Fang, Man Chen, Meng Qi Wang, Wei Lin This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7610425/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 04 Feb, 2026 Read the published version in Respiratory Research → Version 1 posted 8 You are reading this latest preprint version Abstract Objective This study aimed to combine network pharmacology with in vitro experiments to identify the key targets and potential mechanisms of salidroside (Sal) in the treatment of acute lung injury (ALI). Methods Potential targets related to Sal and ALI were retrieved from the ChEMBL, SuperPRED, SwissTargetPrediction, GeneCards, OMIM, and CTD databases. Overlapping targets were imported into the STRING database and Cytoscape software to construct a protein-protein interaction (PPI) network and identify core targets. Functional enrichment analysis of these core genes, including GO and KEGG pathways, was performed using the DAVID database. Two genes, MAPK14 and GPX4, directly relevant to subsequent validation, were selected for molecular docking analysis. Furthermore, an in vitro model of ALI was established using LPS-induced alveolar type II epithelial cells to verify the protective mechanism of Sal. Results A total of 355 potential targets associated with Sal in ALI treatment were identified. In vitro experiments showed that, compared to the LPS group, the Sal group exhibited significantly reduced secretion of IL-6, ROS, p-MAPK, MDA, and Fe²⁺, along with increased GPX4 expression and attenuated lung injury. Conclusion Integrated network pharmacology and experimental validation suggest that Sal pretreatment alleviates inflammatory response and oxidative stress, likely through regulation of the MAPK/GPX4 signaling pathway, thereby providing protection against lung tissue injury. Network pharmacology Salidroside Acute lung injury Molecular mechanism Ferroptosis Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8 Figure 9 Figure 10 Figure 11 Figure 12 Figure 13 Figure 14 Introduction Acute lung injury (ALI) and its most severe form, acute respiratory distress syndrome (ARDS), are life-threatening conditions characterized by widespread diffuse damage to alveolar epithelial cells (AECII) and uncontrolled inflammation. These conditions manifest as bilateral pulmonary opacities on imaging accompanied by severe hypoxemia( 1 , 2 ). The underlying mechanisms are highly complex, involving an imbalance in inflammatory responses, regulation of aquaporins, dysregulation of coagulation/fibrinolysis systems, apoptosis, autophagy, fever, among others( 3 ). Despite significant efforts directed towards the immune response against infections—exacerbated by the emergence of novel pathogens such as the global pandemic of COVID-19( 4 , 5 ), and the ongoing rise in drug resistance, effective pharmacological therapies for ALI remain elusive( 6 ). Increasing evidence suggests that acute lung injury is closely associated with non-apoptotic pathways including pyroptosis( 7 – 9 )and ferroptosis( 10 – 12 ). Ferroptosis is a recently identified form of regulated cell death distinct from necrosis and apoptosis; it is characterized by iron-dependent accumulation of lipid peroxides (LPO)( 13 )and manifests through decreased activity of key antioxidant enzymes such as GPX4 within the glutathione system( 14 ). Iron deposition has been observed in the lower respiratory tract of ALI patients; this accumulation can lead to inflammatory responses, oxidative stress, and mitochondrial dysfunction which further exacerbate lung injury severity( 15 ). A deeper understanding of the molecular mechanisms underlying ferroptosis in ALI may provide new therapeutic avenues for treating acute lung injury. Previous studies have indicated that traditional Chinese medicine exhibits therapeutic effects on sepsis-induced acute lung injury( 16 – 18 ). Salidroside is a bioactive component derived from Rhodiola rosea. Its antioxidative properties( 19 ), anti-aging effects( 20 ), anticancer activities( 21 ), and immunomodulatory functions( 22 )have been widely validated. Our prior research demonstrated that salidroside could prevent sepsis-related acute lung injury while reducing pro-inflammatory cytokine production( 23 ), highlighting its potential clinical value. Network pharmacology offers insights into disease pathogenesis and progression from a systems biology perspective; it can elucidate the actions of traditional Chinese medicines( 24 ). Molecular docking serves as a computational method to assess binding affinities between small molecules and specific receptors through active component screening( 25 ). Therefore, we employed network pharmacology alongside molecular docking techniques to uncover the mechanistic pathways through which salidroside exerts its therapeutic effects on ALI. Finally, we conducted further validation at the cellular level regarding both efficacy and mechanism. Materials and Methods 1.1 Network Pharmacology and Molecular Docking 1.11 Target Identification for Salidroside The compound Salidroside was input into the PubChem database (https://pubchem.ncbi.nlm.nih.gov/)(26)to obtain its SMILES identifier. Subsequently, this identifier was entered into the SwissTargetPrediction database (http://www.swisstargetprediction.ch/)(27), where targets with a Probability > 0 were selected, along with data from the CHEMBL database (https://www.ebi.ac.uk/chembl/)(28)and Super-PRED database (https://prediction.charite.de)(29). The species filter was restricted to "Homo sapiens". Target proteins were standardized using the UniProt database (https://www.uniprot.org). After integrating prediction results and removing duplicates, a final list of target genes for Rhodiola rosea glycoside was compiled(30). 1.12 Acquisition of Acute Lung Injury Targets Targets associated with acute lung injury were primarily sourced from GeneCards (https://www.genecards.org/)(31), OMIM (https://www.omim.org/)(32)and CTD databases (https://ctdbase.org)(33)，by searching for the keyword "acute lung injury" .Following integration and removal of duplicate target genes across these three databases, a set of disease-specific target genes related to acute lung injury was obtained. 1.13 Core Gene Identification Venny 2.1 online software tool (https://bioinfogp.cnb.csic.es/tools/venny/) was utilized to analyze common action targets between Rhodiola rosea glycoside and acute lung injury in order to identify shared drug-disease targets. A protein-protein interaction network diagram was constructed using the STRING online platform (https://string-db.org/)(34)with species limited to "Homo sapiens" and a confidence score set at ≥ 0.9. This network data was then imported into Cytoscape 3.8.2, where core genes were ranked based on values assigned through topological network algorithms via the cytoHubba plugin for further exploration and analysis of core gene networks. 1.14 GO and KEGG Pathway Enrichment Analysis To further investigate the mechanism of Rhodiola rosea glycoside in treating acute lung injury (ALI), core genes were submitted to the DAVID database (https://david.ncifcrf.gov/)(35)for Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. The GO enrichment analysis was visualized using bubble plots that display the top ten biological processes, cellular components, and molecular functions, while a bar chart illustrated the top twenty KEGG pathways. 1.15 Molecular Docking The structure of Rhodiola rosea glycoside was obtained from the PubChem database, converted into a three-dimensional format, and saved in *MOL format. AutoDock version 1.5.6 was used to process this structure, saving it as a *PDBQT file. The crystal structure of the target protein was retrieved from the PDB database (http://www.RLsb.org). PyMol and AutoDock software were employed to manipulate the target protein molecule, which was also saved in *PDBQT format. Using AutoDock-Vina, molecular docking between Rhodiola rosea glycoside and the target protein was performed; results were visualized using PyMol version 1.7.x. 1.2 Cell Experiments 1.21 Cells and reagents Rat alveolar type II epithelial cells (RLE-6TN) were purchased from Hunan Fenghui Biotechnology Co., Ltd.; CCK-8 assay kit (Lot: C0038) was obtained from Shanghai Biyuntian Biotechnology Co., Ltd.; ANNEXIN V-FITC/PI apoptosis detection kit (Lot: CA1020) was sourced from Beijing Solarbio Technology Co., Ltd.; H2DCFDA (Synonyms: DCFH-DA; 2',7'-Dichlorodihydrofluorescein diacetate) (Lot: 4091990) was acquired from MedChemExpress in the USA; Fe2+ ELISA kit (Lot: BC5415) was purchased from Beijing Solarbio Technology Co., Ltd.; MDA ELISA kit (Lot: S0131S) was obtained from Shanghai Biyuntian Biotechnology Co., Ltd.; TBST wash buffer was sourced from Beijing Solarbio Technology Co., Ltd.; antibody dilution buffer and 5% BSA blocking solution were both purchased from Beijing Zhongshu Jinqiao Biotechnology Co., Ltd. The GPX4 Monoclonal antibody (Lot: 67763-1-Ig, dilution ratio 1:5000 for a molecular weight of 20 kDa) was acquired from Proteintech in the USA; Anti-CD130 (gp130) antibody [EPR24557-50] (Lot: ab283685, dilution ratio 1:1000 for a molecular weight of 130 kDa), Anti-IL-6 antibody [EPR23819-103] (Lot: ab290735, dilution ratio 1:1000 for a molecular weight of 23 kDa), and Anti-p38 phospho T180 + Y182 antibody(Lot: ab4822, dilution ratio 1:1000 for a molecular weight of 38 kDa) were all sourced from Abcam in the UK. The p38 MAPK Polyclonal antibody (Lot：14064-1-AP，dilution ratio：1：5000，molecular weight：38 kDa) was obtained from Proteintech in the USA; Beta Actin Monoclonal antibody (Lot：29380-1-AP，dilution ratio：1：5000，molecular weight：42 kDa）was also acquired from Proteintech; Goat Anti-Mouse IgG/HRP（Lot：SE131，dilution ratio：1：2000）was purchased from Beijing Solarbio Technology Co., Ltd.; Goat Anti-Rabbit IgG H&L (HRP) (Lot : ab6721 , dilution rate : 1 :2000 ) came from Abcam Limited in the UK. 1.22 Cell culture Cell Culture Rat alveolar type II epithelial cells (RLE-6TN) were cultured using DMEM complete medium, which was prepared by adding 10% fetal bovine serum and 1% antibiotics. Both cell lines were placed in an incubator containing 95% O2 and 5% CO2, maintained at a constant temperature of 37°C. Once the cells reached approximately 90% confluence, they were digested for passage using 0.25% trypsin, with logarithmic phase cells being used for experimental procedures. 1.23 Cell proliferation detection CCK-8 Assay for Cell Proliferation RLE-6TN cells were seeded in a 96-well plate, with a total volume of culture medium per well set to 200 μl. The groups included: culture medium group containing cells (control group), LPS group (5 μg/ml), and LPS+Sal group (40 μg/ml). After drug treatment for eight hours, CCK-8 reagent (20 μl) was added to each well, followed by incubation in the incubator for an additional period of one to four hours until the color developed into deep brown. Subsequently, the optical density (OD) value of each well was measured at a wavelength of 450 nm using a microplate reader. The percentage of cell proliferation was calculated as follows: Cell proliferation percentage = [(Experimental Group OD - Blank Group OD) / (Control Group OD - Blank Group OD)] ×100%. 1.24 Cell apoptosis detection Flow Cytometry Detection of Apoptosis After appropriate culture stimulation, all cells along with their culture medium were transferred into centrifuge tubes and centrifuged at room temperature at 1000 rpm for five minutes to remove the supernatant. Cells were then resuspended in PBS solution (3 ml), followed by another round of centrifugation under the same conditions; this step was repeated twice more before resuspending the final pellet in binding buffer solution while removing excess supernatant after each spin cycle. For staining, each sample received a mixture consisting of 100 μl binding buffer along with Annexin V and PI staining solution (5 μl each). The samples were gently mixed and incubated at room temperature away from light for fifteen minutes before undergoing another centrifugation step at room temperature at 1000 rpm for five minutes to discard supernatants again; finally, they were resuspended in PBS solution prior to immediate analysis via flow cytometry. 1.25 ROS detection Flow Cytometry Detection of ROS Concentration A stock solution comprising H2DCFDA dissolved in DMSO was prepared by dissolving five milligrams into one point zero three milliliters DMSO as needed; subsequently diluted with pre-warmed serum-free cell culture media or PBS to achieve working concentrations ranging from five to ten micromolar H2DCFDA solutions according to manufacturer instructions. 1.26 ELISA detection of Fe 2+ and MDA ELISA Detection of Fe 2+ and MDA Concentrations Cell supernatants were collected, and the concentrations of Fe 2+ and MDA were measured according to the instructions provided in the Fe 2+ and MDA ELISA kit. The optical density values for each well were determined using a microplate reader at a wavelength of 450 nm. 1.27 Immunofluorescence detection of GPX4 Immunofluorescence Detection of GPX4 Concentration To assess the protein levels of glutathione peroxidase 4 (GPX4) in cells, treated RLE-6TN cells were seeded onto glass-bottom culture dishes. After treatment, cells were fixed with 4% paraformaldehyde at room temperature for 15 minutes, followed by permeabilization with 0.1% Triton X-100 for 10 minutes. Subsequently, cells were blocked in PBS containing 5% bovine serum albumin at room temperature for one hour. Cells were then incubated overnight at 4 °C with a primary antibody specific to GPX4. Following PBS washes, cells were incubated in the dark at room temperature for one hour with an Alexa Fluor 488-conjugated goat anti-rabbit IgG secondary antibody. The cell nuclei were counterstained with DAPI (1 μg/mL) for five minutes. Finally, samples were mounted using an anti-fade mounting medium. All images from samples were acquired using a microscope model such as Nikon A1R+ laser confocal microscope under a ×60 oil immersion objective lens to ensure reliable comparisons of fluorescence intensity; all experimental groups and control groups underwent staining within the same batch while utilizing identical microscopy parameters during image acquisition. 1.28 Western blot Protein Immunoblotting Analysis Cell samples from four different groups were collected and lysed using RIPA buffer supplemented with PMSF (100 mM) in a ratio of 100 µL RIPA + 1 µL PMSF by pipetting gently before placing on ice for thirty minutes post-lysis; subsequently centrifuged at 12,000 rpm for thirty minutes at 4°C after lysis completion. Protein concentration was quantified using BCA assay kits following their operational protocols. For protein blotting analysis, BeyoECL Plus reagent kit (P0018S; Beyotime, China) was employed along with imaging performed via Tanon Imaging System (Tanon, China). 2. Statistical analysis The results are expressed as mean ± SD. Use unpaired two-sided student t-tests for two group comparisons or one-way ANOVA tests, and then use Bonferroni post hoc tests for multiple comparisons to analyze differences. P <0.05 is considered to indicate significant statistical differences. Results 3.1 Network Pharmacology and Molecular Docking Results The results of network pharmacology and molecular docking indicate that Salidroside exerts its therapeutic effects on acute lung injury (ALI) through a synergistic action involving multiple targets and pathways. The flowchart is illustrated in Figure 1. Figure 1. Flow Chart of Network Pharmacology and Molecular Docking. 3.11 Intersection Genes between Salidroside and Acute Lung Injury In this study, we identified 382 targets associated with Salidroside from the ChEMBL, Swiss TargetPrediction, and Super-PRED databases. Subsequently, we determined 11,036 targets closely related to ALI using the GeneCards, OMIM, and CTD databases. Through Venn diagram analysis, we obtained a set of 355 overlapping targets as potential candidates for Salidroside treatment of ALI (Figure 2). Figure 2. The Venn diagram of related targets between Sal and ALI. 3.12 Protein Interaction Network Diagram and Core Genes Acquisition Using the STRING database along with Cytoscape software, we constructed a protein-protein interaction network diagram for detailed analysis to gain insights into the topological features of these nodes. This visualization effectively conveys the significance of each node through size and color; it includes 213 nodes and 470 edges where larger nodes with darker colors represent higher degree values within the network (Figure 3A). Further analysis utilizing the cytoHubba plugin in Cytoscape allowed us to identify 20 key targets involved in Salidroside's treatment of ALI (Figure 3B). Figure 3. Protein-protein interaction network diagram and Core Genes Acquisition. A: Protein-protein interaction network diagram; B: Core Genes. 3.13 GO and KEGG Pathway Analysis for Sal Treatment in ALI The top twenty key genes were imported into the DAVID database for Gene Ontology (GO) enrichment analysis as well as KEGG pathway enrichment analysis. The GO enrichment results indicated involvement in 190 biological processes, 28 cellular components, and 44 molecular functions. We selected the top ten entries from each category which are visually represented in an enrichment chart (Figure 4), providing a clear overview related to Salidroside’s therapeutic effects on ALI—primarily concerning signal transduction, cytosol localization, protein binding among others. The KEGG pathway enrichment analysis revealed associations with151 signaling pathways predominantly linked to MAPK signaling pathway and VEGF signaling pathway; details regarding the top twenty results are shown in Figure5. Figure 4. GO enrichment analysis . Figure 5. KEGG enrichment analysis. 3.14 Molecular Docking Molecular docking analysis was conducted between Sal and two genes related to the study, MAPK14 and GPX4. The results highlighted the strong binding affinity of Sal to these key proteins (Table 1). To further elucidate the complex binding configurations, we utilized PyMOL for visualization, displaying the lowest energy binding conformation (Figure 6). This visualization vividly illustrates the close relationship between Sal and its critical targets, providing valuable insights into their interaction's structural basis and reinforcing the significance of Sal in treating ALI at a molecular level. Table 1. Verification results of molecular docking Ingredients targets Affifinity (kcal/mol) Distance from best mode rmsd l.b. rmsd u.b. Salidroside MAPK14 - 6.7 0 0 GPX4 - 6.4 0 0 Figure 6. Molecular Docking. A: Salidroside with MAPK14; B: Salidroside with GPX4. 3.2 Cellular Experimental Results Acute lung injury caused by septic infection leads to widespread diffuse damage and uncontrolled inflammation in alveolar epithelial cells. Therefore, this study selected rat alveolar type II epithelial cells for subsequent research; the flowchart is shown in Figure 7. Figure 7. Cell experiment flowchart. 3.21 Cell Proliferation Assay The proliferation of cells from different groups was assessed using a CCK-8 kit, as illustrated in Figure 8. The cell proliferation rate in the LPS group was significantly lower than that of the control group ( P <0.01); however, upon addition of Sal, there was an increase in cell proliferation rate compared to the LPS group ( P <0.05). This suggests that Sal can mitigate LPS-induced cytotoxicity and enhance cell viability. Figure 8. Changes in proliferation rate of RLE-6TN cells treated with Sal. ## P <0.01 VS Control group; * P <0.05 VS LPS group; Mean ± SD, n=3. 3.22 Cell Apoptosis Assay As depicted in Figure 9, apoptosis detection across different groups revealed that the apoptosis rate in the LPS group was significantly higher than that of the control group ( P <0.01); following treatment with Sal, there was a decrease in apoptosis rate compared to the LPS group (P<0.05). This indicates that Sal may inhibit LPS-induced apoptosis and improve cell viability. Figure 9. Changes in apoptosis rate of RLE-6TN cells treated with Sal. ## P <0.01 VS Control group; * P <0.05 VS LPS group; Mean ± SD, n=3. 3.33 ROS Detection ROS levels were measured using an ROS detection kit across various groups as shown in Figure 10; it was found that ROS content in the LPS group was significantly higher than that of controls ( P <0.01). After adding Sal, ROS levels decreased compared to those observed with LPS alone ( P <0.05), suggesting that Sal can suppress oxidative stress induced by LPS on cells. Figure 10. Changes in ROS content in RLE-6TN cells treated with Sal. ## P <0.01 VS Control group; * P <0.05 VS LPS group; Mean ± SD, n=3. 3.34 ELISA Detection of Fe 2+ and MDA As presented in Figure 11, both Fe 2+ and MDA levels were significantly elevated in comparison with controls within the LPS group ( P <0.01); conversely, Fe 2+ and MDA concentrations were markedly reduced after treatment with Sal when compared to those seen with just LPS exposure ( P <0.01). These findings indicate that Sal may inhibit iron death and lipid peroxidation triggered by LPS. Figure 11. Changes in Fe 2+ and MDA content in RLE-6TN cells treated with Sal. A: Changes in Fe 2+ content, B: Changes in MDA content; ## P <0.01 VS Control group, ** P <0.01 VS LPS group; Mean ± SD, n=3. 3.35 Immunofluorescence Detection of GPX4 To verify changes regarding GPX4 among different cellular groups, immunofluorescence detection for GPX4 was performed as illustrated in Figure 12; it showed significant reductions in immunofluorescence intensity for GPX4 within samples fromtheL PSgroup relative to controls; however ,followingSal treatment ,GPX4 immunofluorescence intensity increased substantially when comparedtoL PSalone . Figure 12. Changes in immunofluorescence intensity of GPX4 in RLE-6TN cells treated with Sal. n=3. 3.36 Western Blot To elucidate the associated pathways, we conducted Western blot analysis on GPX4, gp130, IL-6, MAPK, and p-MAPK. As illustrated in Figure 13, compared to the control group, the LPS group exhibited significantly elevated levels of gp130, IL-6, and p-MAPK ( P <0.01). Following the administration of Sal, there was a notable decrease in the levels of gp130, IL-6, and p-MAPK when compared to the LPS group ( P <0.01). Conversely, while GPX4 levels were significantly reduced in the LPS group relative to the control group ( P <0.01), a marked increase in GPX4 was observed in the Sal group compared to the LPS group ( P <0.01). These findings suggest that Sal may mitigate lung injury by modulating the MAPK/GPX4 pathway. Figure 13. Western blot was used to detect the protein expression of GPX4 、 gp130 、 IL-6 、 MAPK and p-MAPK in cells. Discussion Acute lung injury arises from widespread damage to the pulmonary microvascular endothelium and alveolar epithelium triggered by severe infection, shock, trauma or burns. Clinically it manifests as diffuse interstitial and alveolar oedema culminating in acute hypoxaemic respiratory insufficiency that can progress to life-threatening ARDS(36-38). To date, no pharmacological agent has been approved specifically for ALI, and off-label therapies frequently provoke coagulopathy, gastric ulceration or osteoporosis(39). By contrast, syndrome-based Chinese medicine employs either purified herbal monomers or multi-compound formulae to prevent or treat ALI/ARDS with encouraging results(40). Salidroside, the principal bioactive constituent of Rhodiola rosea, has been reported to attenuate ALI through antioxidant and anti-inflammatory actions(23, 41, 42); nevertheless, the precise molecular circuitry remains ill-defined. Here we integrated network pharmacology with molecular docking to map the therapeutic interactome of salidroside in ALI and subsequently validated the predictions experimentally in vitro. Our data demonstrate that (1) salidroside exerts protective effects against ALI via a multi-target, multi-pathway mechanism, and (2) salidroside suppresses LPS-evoked accumulation of ROS, Fe²⁺, MDA and IL-6, dampens p-MAPK signalling, while restoring GPX4 expression. GO enrichment analysis revealed that ALI-relevant biological processes are enriched in signal transduction and protein phosphorylation. At the cellular-compartment level, salidroside preferentially modulates proteins localized to the cytoplasm and nucleus. Molecular-function profiling further indicated that ALI perturbs both protein-binding and ATP-binding capacities. KEGG pathway mapping identified MAPK, mTOR and VEGF cascades as the most significantly represented signalling routes—networks intimately linked to cell proliferation, differentiation, apoptosis and immune–inflammatory responses—thereby positioning salidroside as a promising botanical monomer for ALI prophylaxis and therapy. Independent studies corroborate these in silico predictions. Guo et al.(41)reported that salidroside suppresses hyperoxia-induced AECⅡ ferroptosis via blockade of the p38 MAPK axis, reversing hyperoxic lung injury in neonatal rats. Similarly, in LPS-challenged rodents, salidroside down-regulated p38 MAPK phosphorylation and ameliorated ALI histopathology(43), findings that align closely with our observations. The mTOR pathway has also been implicated in ALI pathobiology; salidroside attenuated lung damage by curtailing mTOR phosphorylation in rat models of endotoxin shock(44). Regarding VEGF signalling, earlier work suggests a contextual, time-dependent role: early VEGF release increases pulmonary vascular permeability, whereas sustained depletion of VEGF/VEGFR-1 compromises alveolar epithelial viability(45). Conversely, activation of macrophage-specific VEGF-C/VEGFR-3 signalling ameliorated LPS-induced ALI by enhancing resolution of alveolar inflammation(46). Collectively, these data implicate salidroside-mediated fine-tuning of MAPK, mTOR and VEGF networks as a central mechanism underlying its protective effects against ALI. Molecular docking results revealed that Sal exhibited favorable binding affinities to MAPK14 (p38MAPK) and GPX4, with binding energies of -6.7 and -6.4 kcal/mol, respectively. This suggests that Sal may exert therapeutic effects on ALI by modulating these two target genes. Yang et al.(47)demonstrated that in an LPS-induced ALI model, phosphorylation levels of p38MAPK were significantly elevated, and inhibition of p38MAPK phosphorylation markedly alleviated ALI symptoms. Similarly, Zhang et al.(48)reported that in pediatric sepsis-induced ALI, overexpression of MAPK14 enhanced oxidative stress, lipid peroxidation, iron accumulation, promoted neutrophil infiltration, and upregulated PD-L1 expression, leading to immunosuppression. Knockdown of MAPK14 reduced ferroptosis and attenuated ALI, which is consistent with our findings. Furthermore, Wu et al.(49)identified MAPK14 as a hub gene potentially playing a critical role in the inflammatory regulation of ALI through bioinformatic analysis. Numerous studies have also indicated that phosphorylated p38MAPK levels are significantly increased in ALI, and inhibition of its phosphorylation via traditional Chinese medicine substantially alleviated ALI symptoms(50, 51). As a key marker of ferroptosis(52), GPX4 expression was found to be significantly reduced in ALI, promoting ferroptotic cell death. Treatment with herbal medicine was shown to upregulate GPX4 levels, suppress ferroptosis, and consequently ameliorate ALI(53-55). The present study demonstrated that Sal effectively reduced the expression levels of IL-6 and ROS in ALI. Wu et al.(56)reported that during sepsis, pulmonary capillary endothelial cells stimulated by cytokines such as IL-1, IL-6, and TNF-α exhibit increased vascular permeability, leading to the leakage of plasma components (including water and proteins) into the alveolar space and resulting in pulmonary edema. Inhibition of IL-6 expression has been shown to alleviate ALI(57-59). Additionally, in ALI, excessive ROS production damages pulmonary vascular endothelial cells, promotes fluid leakage, and exacerbates lung injury(60). Suppression of ROS generation has been found to reverse ALI symptoms(61-63). These findings are consistent with our results, indicating that reduction in IL-6 and ROS levels can lead to the amelioration of ALI. Nevertheless, this study has certain limitations. Future investigations will focus on the following aspects:(1) Examining downstream proteins of MAPK signaling and other proteins associated with ferroptosis; (2) Establishing in vivo models to validate whether Sal mitigates acute lung injury through this pathway. Conclusion In summary, Sal was identified through network pharmacology and molecular docking as a promising active compound for the treatment of ALI. Preliminary in vitro experiments demonstrated that Sal pretreatment attenuates inflammatory response and oxidative stress, thereby conferring protection to lung tissue, likely via modulation of the MAPK/GPX4 signaling pathway (Fig. 14). These findings suggest that salidroside may serve as a potential therapeutic agent against LPS-induced ALI. Figure 14. Schematic of the protective mechanism of Sal against LPS-induced ALI. Sal inhibits the IL-6-gp130 interaction, thereby suppressing the MAPK/GPX4 pathway. This leads to the downregulation of ROS, MDA, and Fe²⁺, ultimately inhibiting ferroptosis in alveolar epithelial cells. Abbreviations Sal Salidroside ALI Acute lung injury GO gene ontology IL-6 Interleukin-6 KEGG Kyoto Encyclopedia of Genes and Genomes LPS Lipopolysaccharide ARDS Acute Respiratory Distress Syndrome LPO Lipid peroxides MDA Malondialdehyde IL-1 Interleukin-1 GPX4 Glutathione Peroxidase 4 CCK8 Cell Counting Kit-8 mTOR Mammalian target of rapamycin TNF-α Tumor Necrosis Factor-α VEGF Vascular endothelial growth factor ROS Reactive oxygen species Declarations Acknowledgements We want to acknowledge the support of our institution and resources. Funding This work was funded by the National Natural Science Foundation of China (82471061), Shandong Natural Science Foundation (ZR2023MH035), and Youth Science Foundation Cultivation Support Program (Natural Science) of Shandong First Medical University &Shandong Academy of Medical Sciences (202201-009). CRediT authorship contribution statement Min Zhao: Software, Validation, Formal analysis, Writing—review & editing. Min Zhao and Meng Qi Wang: Conceptualization, Writing—original draft. Wei Fang and Man Chen: Conceptualization, Investigation, Supervision and Editing. Wei Lin: Supervision, Writing—review & editing. Ethics approval and consent to participate Not applicable. Competing interests The authors declare that they have no competing interests. Data availability The Data is provided within the manuscript or supplementary information files. References Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome. Lancet. 2021;2021(1/1):622–37. Silva JD, Su Y, Calfee CS, Delucchi KL, Weiss D, McAuley DF et al. Mesenchymal stromal cell extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS. EUR RESPIR J. 2021 2021/1/1;58(1). Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, et al. Acute respiratory distress syndrome. NAT REV DIS PRIMERS. 2019;2019/1/1(1):18. Khan G, Sheek-Hussein M, Al Suwaidi AR, Idris K, Abu-Zidan FM. Novel coronavirus pandemic: A global health threat. TURK J EMERG MED. 2020;2020/1(120):55–62. Vaninov N. In the eye of the COVID-19 cytokine storm. NAT REV IMMUNOL. 2020;2020(1/1):277. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. MICROBIOL MOL BIOL R. 2012;2012/1(1):16–32. Li D, Ren W, Jiang Z, Zhu L. Regulation of the NLRP3 inflammasome and macrophage pyroptosis by the p38 MAPK signaling pathway in a mouse model of acute lung injury. MOL MED REP. 2018;2018/1(1):4399–409. Hou L, Yang Z, Wang Z, Zhang X, Zhao Y, Yang H, et al. NLRP3/ASC-mediated alveolar macrophage pyroptosis enhances HMGB1 secretion in acute lung injury induced by cardiopulmonary bypass. LAB INVEST. 2018;2018(1/1):1052–64. Dahao L, Ju G. Research progress on the role of cell pyroptosis in sepsis induced acute lung injury. J Clin Anesthesiology. 2024;2024(1/1):412–5. Liu P, Feng Y, Li H, Chen X, Wang G, Xu S, et al. Ferrostatin-1 alleviates lipopolysaccharide-induced acute lung injury via inhibiting ferroptosis. CELL MOL BIOL LETT. 2020;2020/1(1):10. Qiang Z, Dong H, Xia Y, Chai D, Hu R, Jiang H. Nrf2 and STAT3 alleviates ferroptosis-mediated IIR‐ALI by regulating SLC7A11. OXID MED CELL LONGEV. 2020 2020/1/1;2020(1):5146982. Guo D, Cai S, Deng L, Xu W, Fu S, Lin Y et al. Ferroptosis in pulmonary disease and lung cancer: molecular mechanisms, crosstalk regulation, and therapeutic strategies. MEDCOMM. 2025 2025/1/1;6(3):e70116. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;2012/1(1):1060–72. Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. CELL RES. 2019;2019(1/1):347–64. Ghio AJ, Carter JD, Richards JH, Richer LD, Grissom CK, Elstad MR. Iron and iron-related proteins in the lower respiratory tract of patients with acute respiratory distress syndrome. CRIT CARE MED. 2003;2003/1(1):395–400. Wenyu W, Nuoran L, Kai W, Xin J, Wanning L, Yunsheng X et al. Research progress and exploration of traditional Chinese medicine inhibiting cell pyroptosis in the treatment of sepsis induced acute lung injury. Chin J Chin Mater Med. 2025:1–13. Yiju L, Dengjun J. Research progress on traditional Chinese medicine compound therapy for acute lung injury based on NF - κ B signaling pathway. Hunan J Traditional Chin Med. 2025;41(01):171–4. Chenfei F, Qun L, Jianlong L. Research progress on the treatment of sepsis induced acute lung injury with traditional Chinese medicine monomers. J changchun Univ traditional Chin Med. 2024;40(02):219–25. Hou Y, Fan F, Xie N, Zhang Y, Wang X, Meng X. Rhodiola crenulata alleviates hypobaric hypoxia-induced brain injury by maintaining BBB integrity and balancing energy metabolism dysfunction. Phytomedicine. 2024 2024/1/1;128:155529. Mu L, Wang G, Yang X, Liang J, Tong H, Li L et al. Physiological premature aging of ovarian blood vessels leads to decline in fertility in middle-aged mice. NAT COMMUN. 2025 2025/1/1;16(1):72. Huang G, Cai Y, Ren M, Zhang X, Fu Y, Cheng R, et al. Salidroside sensitizes Triple-negative breast cancer to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy. J ADV RES. 2025;2025/1(/1):74:589–607. Shuyi N, Zhao J, Zhongtao W, Shumei H. The effect of salidroside on the immune function of macrophages infected with BCG vaccine. J Shanghai Jiao Tong Univ (Medical Edition). 2025;2025(1/1):426. Song D, Zhao M, Feng L, Wang P, Li Y, Li W. Salidroside attenuates acute lung injury via inhibition of inflammatory cytokine production. BIOMED PHARMACOTHER. 2021 2021/1/1;142:111949. Zhang P, Zhang D, Zhou W, Wang L, Wang B, Zhang T, et al. Network pharmacology: towards the artificial intelligence-based precision traditional Chinese medicine. BRIEF BIOINFORM. 2024;2024/1(1):bbad518. Rudrapal M, Chetia D. Virtual screening, molecular docking and QSAR studies in drug discovery and development programme. J drug delivery Ther. 2020;2020/1(1):225–33. Kim S, Chen J, Cheng T, Gindulyte A, He J, He S et al. PubChem 2025 update. NUCLEIC ACIDS RES. 2025 2025/1/1;53(D1):D1516–25. Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. NUCLEIC ACIDS RES. [Journal Article; Research Support, Non-U.S. Gov't]. 2014 2014/7/1;42(Web Server issue):W32–8. Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, et al. ChEMBL: towards direct deposition of bioassay data. NUCLEIC ACIDS RES. 2019;2019(1/147D1):D930–40. Deng J, Wei L, Chen Y, Li X, Zhang H, Wei X, et al. Identification of benzo (a) pyrene-related toxicological targets and their role in chronic obstructive pulmonary disease pathogenesis: a comprehensive bioinformatics and machine learning approach. BMC Pharmacol Toxicol. 2025;2025/1(1):33. U C. UniProt: the Universal Protein Knowledgebase in 2025. NUCLEIC ACIDS RES. [Journal Article]. 2025 2025/1/6;53(D1):D609–17. Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M et al. GeneCards Version 3: the human gene integrator. DATABASE-OXFORD. [Journal Article; Research Support, Non-U.S. Gov't]. 2010 2010/8/5;2010:baq20. Amberger JS, Hamosh A. Searching online mendelian inheritance in man (OMIM): a knowledgebase of human genes and genetic phenotypes. Curr protocols Bioinf. 2017;2017/1/(1):1–2. Davis AP, Wiegers TC, Sciaky D, Barkalow F, Strong M, Wyatt B et al. Comparative toxicogenomics database’s 20th anniversary: update 2025. NUCLEIC ACIDS RES. 2025 2025/1/1;53(D1):D1328-34. Szklarczyk D, Nastou K, Koutrouli M, Kirsch R, Mehryary F, Hachilif R et al. The STRING database in 2025: protein networks with directionality of regulation. NUCLEIC ACIDS RES [Journal Article]. 2025 2025/1/6;53(D1):D730–7. Dennis GJ, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. GENOME BIOL. [Journal Article; Research Support, U.S. Gov't, P.H.S.]. 2003 2003/1/20;4(5):P3. Huppert LA, Matthay MA, Ware LB. Pathogenesis of acute respiratory distress syndrome. Thieme Med Publishers. 2019 2019/1/1;40:31 – 9. Reilly JP, Calfee CS, Christie JD. Acute respiratory distress syndrome phenotypes. Thieme Med Publishers. 2019;2019/1(/1):40:19–30. Ghasemzadeh Rahbardar M, Razavi BM, Naraki K, Hosseinzadeh H. Therapeutic effects of minocycline on oleic acid-induced acute respiratory distress syndrome (ARDS) in rats. Naunyn-schmiedeberg's Archives of Pharmacology. 2023 2023/1/1;396(11):3233–42. Zhao M, Lv G, Huang X, Niu Y, Zhang Q, Li W. Mechanism and Experimental Verification of Rhodiola rosea L. for the Treatment of Acute Lung Injury Through Network Pharmacology and Molecular Docking. NAT PROD COMMUN. 2024;2024(1/1):1934578X241245550. Angang L, Xiao L, Junmei L, Cong P, Jianxun L. Research progress on traditional Chinese medicine regulating oxidative stress and intervening in acute lung injury. Chin J Experimental Traditional Med Formulae. 2025;31(10):305–12. Guo B, Zuo Z, Di X, Huang Y, Gong G, Xu B, et al. Salidroside attenuates HALI via IL-17A-mediated ferroptosis of alveolar epithelial cells by regulating Act1-TRAF6-p38 MAPK pathway. CELL COMMUN SIGNAL. 2022;2022/1(1):183. Haoting M, Guanglan X, Mei Z, Wenjiao Y, Guangyao W, Dan Y, et al. Research progress on the protective effect of salidroside on acute lung injury. Chin Archives Traditional Chin Med. 2021;39(05):130–2. Changci T, Yunen L, Hongxu J, Yubiao Z, Shilin, Mingxiao H, et al. Study on the protective mechanism of salidroside against lipopolysaccharide induced acute lung injury. J Clin Emerg Med. 2015;16(09):667–71. Yunying X. Exploring the role and mechanism of salidroside in regulating acute lung injury through the PI3K Akt mTOR pathway. Chengdu University of Traditional Chinese Medicine; 2024. Mura M, Han B, Andrade C, Seth R, Hwang D, Waddell TK, et al. The early responses of VEGF and its receptors during acute lung injury: implication of VEGF in alveolar epithelial cell survival. CRIT CARE. 2006;2006(1/1):R130. Yamashita M, Niisato M, Kawasaki Y, Karaman S, Robciuc MR, Shibata Y et al. VEGF-C/VEGFR-3 signalling in macrophages ameliorates acute lung injury. EUR RESPIR J. 2022 2022/1/1;59(4). Yali Y, Rong T, Yin Y, Yanjia W, Xiaoling Y. The role of FoxO1/p38 MAPK signaling pathway in LPS induced acute lung injury. Chin Pharmacol Bull. 2023;39(01):36–42. Zhang N, Fan Y, Chen J, Gu J, Yan X. MAPK14 drives Ferroptosis and immune dysfunction in pediatric Sepsis-induced acute lung injury. CELL IMMUNOL. 2025 2025/1/1;411:104948. Siyang W, Xia H, Pinhu L. Potential diagnostic biomarkers and Mapk14 protein expression: Autophagy-related genes linking immune infiltration in acute respiratory distress syndrome. INT J BIOL MACROMOL. 2024 2024/1/1;279:135077. Zhai Y, Chen K, Xu Z, Chen X, Tong J, He Y, et al. Harmine alleviates LPS-induced acute lung injury by inhibiting CSF3-mediated MAPK/NF-κB signaling pathway. RESP RES. 2025;2025/1(1):1–16. Wang Y, Mou C, Huang L, Su J, You L, Zhang J et al. The ethanolic extract of Rhaphidophora peepla prevents inflammation by inhibiting the activation of Syk/AKT/NF-κB and TAK1/MAPK/AP-1. PHYTOMEDICINE. 2025 2025/1/1;136:156339. Feng C, Yong Z, Xiang W, Jintao D, Zhihao W. Research progress on the role and mechanism of glutathione peroxidase GPX4 in ferroptosis. J Mod Oncol. 2021;29(07):1254–8. Jing L, Jun P, Jing Z, Yun W, Xinyi L. The mechanism of irisin alleviating lipopolysaccharide induced acute lung injury in rats through the Nrf2/GPX4 signaling pathway. New Med Knowl. 2023;33(02):83–90. Li J, Deng S, Li J, Li L, Zhang F, Zou Y, et al. Obacunone alleviates ferroptosis during lipopolysaccharide-induced acute lung injury by upregulating Nrf2-dependent antioxidant responses. CELL MOL BIOL LETT. 2022;2022/1(1):29. Chen H, Xie W, Peng Z, Liu Y, Li H, Huang W. Nobiletin ameliorates heatstroke-induced acute lung injury by inhibiting ferroptosis via p53/SLC7A11 pathway. SHOCK. 2024;2024/1(1):105–11. Wu C, Li H, Zhang P, Tian C, Luo J, Zhang W, et al. Lymphatic flow: a potential target in sepsis-associated acute lung injury. J INFLAMM RES. 2020;2020/1/1:961–8. Yan L, Lei X, Yuzhu S, Xue W. Exploring the protective mechanism of Artemisia annua extract on acute lung injury mice based on NLRP3 inflammatory pathway. CHIN HERB MED. 2025;56(16):5837–46. Zhang J, Zhang M, Huo X, Ning J, Yu Z, Morisseau C, et al. Macrophage inactivation by small molecule wedelolactone via targeting sEH for the treatment of LPS-induced acute lung injury. ACS Cent SCI. 2023;2023/1(1):440–56. Ye Y, Xie M, Nie H, Zhang G, Tu L, Ao M, et al. Investigation of the Effect and Mechanism of Fei Re Pu Qing Powder in Treating Acute Lung Injury (ALI) by Modulating Macrophage Polarization via Serum Pharmacology and Network Pharmacology. J ETHNOPHARMACOL. 2025;2025/1/1:120089. Ying H, Dandan H. Research progress on the correlation between endoplasmic reticulum stress and exacerbation of acute lung injury. J Sun Yat sen Univ (Medical Sci Edition). 2025;46(04):568–73. Zhai Z, Ouyang W, Yao Y, Zhang Y, Zhang H, Xu F et al. Dexamethasone-loaded ROS-responsive poly (thioketal) nanoparticles suppress inflammation and oxidative stress of acute lung injury. Bioactive Mater. 2022 2022/1/1;14:430 – 42. Muhammad W, Liang M, Wang B, Xie J, Ahmed W, Gao C. NAC-grafted ROS-scavenging polymer nanoparticles for modulation of acute lung injury microenvironment in vivo. Biomacromolecules. 2024;2024(1/1):528–40. Luo Z, Wang Q, Fan X, Koh XQ, Loh XJ, Wu C, et al. ROS-Driven Nanoventilator for MRSA‐Induced Acute Lung Injury Treatment via In Situ Oxygen Supply, Anti‐Inflammation and Immunomodulation. ADV SCI. 2025;2025(1/1):2406060. Additional Declarations No competing interests reported. Supplementary Files supplementaryfile.pdf Cite Share Download PDF Status: Published Journal Publication published 04 Feb, 2026 Read the published version in Respiratory Research → Version 1 posted Editorial decision: Revision requested 30 Dec, 2025 Reviews received at journal 10 Nov, 2025 Reviewers agreed at journal 28 Oct, 2025 Reviewers agreed at journal 10 Oct, 2025 Reviewers invited by journal 08 Oct, 2025 Editor assigned by journal 18 Sep, 2025 Submission checks completed at journal 18 Sep, 2025 First submitted to journal 14 Sep, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7610425","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":531625975,"identity":"2426a28d-1d75-4f51-aadf-2a1b39eafb93","order_by":0,"name":"Min Zhao","email":"","orcid":"","institution":"Shandong First Medical University \u0026 Shandong Academy of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Min","middleName":"","lastName":"Zhao","suffix":""},{"id":531625976,"identity":"7aea2658-8fc4-4b55-9bd4-9a36de063ee3","order_by":1,"name":"Wei Fang","email":"","orcid":"","institution":"Shandong Provincial Hospital Affifiliated to Shandong First Medical University","correspondingAuthor":false,"prefix":"","firstName":"Wei","middleName":"","lastName":"Fang","suffix":""},{"id":531625978,"identity":"67e31eab-f686-4200-a9cb-6a56bca00497","order_by":2,"name":"Man Chen","email":"","orcid":"","institution":"Shandong Provincial Hospital Affifiliated to Shandong First Medical University","correspondingAuthor":false,"prefix":"","firstName":"Man","middleName":"","lastName":"Chen","suffix":""},{"id":531625979,"identity":"ca3da6f7-f2dc-4f2e-8b1c-2b6556411676","order_by":3,"name":"Meng Qi Wang","email":"","orcid":"","institution":"Shandong First Medical University \u0026 Shandong Academy of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Meng","middleName":"Qi","lastName":"Wang","suffix":""},{"id":531625980,"identity":"706f98b0-b1a9-4aa8-a453-6a69cf713db9","order_by":4,"name":"Wei Lin","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAuElEQVRIiWNgGAWjYBACPmYgkVDxX46fmfnwA6K0sIG0PDjDbCzZzpZmQJwWIGZ82MacuOE8j4IEcVrYeY9JJLaxGRsf5mEwYKixiSbCYXxpEgnneOTMDvMeeMBwLC23gbAWHrMbCWUSxmaH+RIMGBsOE6uFzSBxczOPgQQJWtoSEjcwk6DF/EfCmQPGEoeBgZxAjF/4+c8YG/6oOCDH33/48IMPNTaEtaCCBNKUj4JRMApGwSjABQA/XjhPsS0c5QAAAABJRU5ErkJggg==","orcid":"","institution":"Shandong First Medical University \u0026 Shandong Academy of Medical Sciences","correspondingAuthor":true,"prefix":"","firstName":"Wei","middleName":"","lastName":"Lin","suffix":""}],"badges":[],"createdAt":"2025-09-14 04:38:12","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7610425/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7610425/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s12931-026-03529-1","type":"published","date":"2026-02-04T15:57:38+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":94024717,"identity":"0e29c377-a445-4e96-b64a-6bb5c6acc3d7","added_by":"auto","created_at":"2025-10-21 13:10:44","extension":"tif","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1999896,"visible":true,"origin":"","legend":"","description":"","filename":"Figure1.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/9b03a7a12d2f7df074ad2692.tif"},{"id":94024724,"identity":"c80e7597-08fd-4d56-8c25-d5e9461feb88","added_by":"auto","created_at":"2025-10-21 13:10:44","extension":"doc","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":377184,"visible":true,"origin":"","legend":"","description":"","filename":"CombiningNetworkPharmacologyandExperimentalValidationtoDemonstrateThatSalidrosideAlleviatesAcuteLungInjurybyInhibitingFerroptosisviatheMAPKGPX4Pathway.doc","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/26692f12603f11335a5bd6b6.doc"},{"id":94024107,"identity":"19e9e389-7f09-420f-a137-61398241d909","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"tif","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":854260,"visible":true,"origin":"","legend":"","description":"","filename":"Figure10.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/999e4377cc4f3b07b20773d4.tif"},{"id":94025122,"identity":"a73e5509-c46c-451b-9ccb-5ed9684ff886","added_by":"auto","created_at":"2025-10-21 13:18:44","extension":"tif","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":404460,"visible":true,"origin":"","legend":"","description":"","filename":"Figure11.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/9210970431fa93257442ecf5.tif"},{"id":94024105,"identity":"7b4b1972-d3bc-4148-985c-e7404dbe672f","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"doc","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":17920,"visible":true,"origin":"","legend":"","description":"","filename":"Table1.doc","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/4b60f01c0f522cdf87a544a6.doc"},{"id":94024726,"identity":"b02e292a-abda-46e1-914e-8ae13fb5dbeb","added_by":"auto","created_at":"2025-10-21 13:10:44","extension":"tif","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":3048368,"visible":true,"origin":"","legend":"","description":"","filename":"Figure12.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/ba0864303786b51526d75cd4.tif"},{"id":94025124,"identity":"939a091e-6684-4bc4-9957-2edf15ac5b73","added_by":"auto","created_at":"2025-10-21 13:18:44","extension":"tif","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1296256,"visible":true,"origin":"","legend":"","description":"","filename":"Figure13.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/9ba25a7dd20daf45d63f1bae.tif"},{"id":94024729,"identity":"406e3f22-8e3f-4d3a-a6de-c0114f2722b6","added_by":"auto","created_at":"2025-10-21 13:10:44","extension":"tif","order_by":7,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":657480,"visible":true,"origin":"","legend":"","description":"","filename":"Figure14.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/9445d826a299b2dec3291b86.tif"},{"id":94024115,"identity":"80a1afa0-a979-4ec6-9095-9e5470a30c69","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"tif","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":246780,"visible":true,"origin":"","legend":"","description":"","filename":"Figure2.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/7e41f943044e1e369139ec1d.tif"},{"id":94024119,"identity":"8adbdfcb-1513-4dd0-9346-80f078bd94bc","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"tif","order_by":9,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1948004,"visible":true,"origin":"","legend":"","description":"","filename":"Figure3.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/579dab3435a7b4e8ba166127.tif"},{"id":94024732,"identity":"b8604079-45ad-4e16-800d-b055f66f2905","added_by":"auto","created_at":"2025-10-21 13:10:44","extension":"tif","order_by":10,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":226620,"visible":true,"origin":"","legend":"","description":"","filename":"Figure4.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/7881fdd61f289a4bf3d055a7.tif"},{"id":94026026,"identity":"8c840cd0-5259-4683-95fb-a1371e660dba","added_by":"auto","created_at":"2025-10-21 13:26:44","extension":"tif","order_by":11,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1033652,"visible":true,"origin":"","legend":"","description":"","filename":"Figure5.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/59f3991f105bebad00fa8593.tif"},{"id":94024741,"identity":"e6cad1fb-6e41-4964-baac-bf30531262c9","added_by":"auto","created_at":"2025-10-21 13:10:45","extension":"tif","order_by":12,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":2448780,"visible":true,"origin":"","legend":"","description":"","filename":"Figure6.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/a9280d8adf7de27fcb956af6.tif"},{"id":94024121,"identity":"9ac9ce2b-cdaf-4bf6-8ac2-9e548b046e1b","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"tif","order_by":13,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1315416,"visible":true,"origin":"","legend":"","description":"","filename":"Figure7.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/4aa47729de46664c8224bd12.tif"},{"id":94024731,"identity":"265caf52-092b-4860-8a12-01fac4e86db8","added_by":"auto","created_at":"2025-10-21 13:10:44","extension":"tif","order_by":14,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":118012,"visible":true,"origin":"","legend":"","description":"","filename":"Figure8.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/d2bbcf8a6ea2fcb997530176.tif"},{"id":94026345,"identity":"185c0adb-2c94-4447-8c4b-a258fbd482f8","added_by":"auto","created_at":"2025-10-21 13:34:45","extension":"tif","order_by":15,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1674180,"visible":true,"origin":"","legend":"","description":"","filename":"Figure9.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/92e20ed328bfbdfc4913ecd8.tif"},{"id":94024122,"identity":"5f0a7192-774a-4c73-9f40-7a2ec519ac06","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"json","order_by":16,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":6532,"visible":true,"origin":"","legend":"","description":"","filename":"14390bc92f794bbd88524f7f14c2273a.json","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/db464e31dd7245752f445d8c.json"},{"id":94024127,"identity":"2ee440bc-9ef7-4b29-a62b-58d35238dbcd","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"pdf","order_by":17,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":215925,"visible":true,"origin":"","legend":"","description":"","filename":"supplementaryfile.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/780177620edeb04d6f3ed920.pdf"},{"id":94024135,"identity":"cfba178e-d502-4763-b8d7-37a1b27a27b9","added_by":"auto","created_at":"2025-10-21 13:02:45","extension":"xml","order_by":18,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":144041,"visible":true,"origin":"","legend":"","description":"","filename":"14390bc92f794bbd88524f7f14c2273a1enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/2136ef81ea939a336e8f8046.xml"},{"id":94024733,"identity":"bef6dde8-3d32-41a2-a07e-7c796a2a11ab","added_by":"auto","created_at":"2025-10-21 13:10:44","extension":"tif","order_by":19,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1999896,"visible":true,"origin":"","legend":"","description":"","filename":"Figure1.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/f5b908cf0e15aae0d0380c68.tif"},{"id":94024734,"identity":"8dfad609-9dc3-46ab-a0bc-7f0448bccdde","added_by":"auto","created_at":"2025-10-21 13:10:45","extension":"tif","order_by":20,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":854260,"visible":true,"origin":"","legend":"","description":"","filename":"Figure10.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/35d7e29f5401f6ecafd07cbc.tif"},{"id":94024128,"identity":"b203f7b2-440d-4df7-8fcb-dd9b9199b1f9","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"tif","order_by":21,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":404460,"visible":true,"origin":"","legend":"","description":"","filename":"Figure11.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/eb8b45db6241c2301c5dea43.tif"},{"id":94024136,"identity":"c1136223-798b-4d85-946a-712cf48c77e0","added_by":"auto","created_at":"2025-10-21 13:02:45","extension":"tif","order_by":22,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":3048368,"visible":true,"origin":"","legend":"","description":"","filename":"Figure12.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/1f7f89e02e7726ec80d13856.tif"},{"id":94024126,"identity":"909ffe66-2376-400a-9975-77306b30e22b","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"tif","order_by":23,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1296256,"visible":true,"origin":"","legend":"","description":"","filename":"Figure13.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/e1fb9a1946eacd497c5e8b52.tif"},{"id":94024131,"identity":"519b2c97-6ba7-4dcb-b13a-ee809087155c","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"tif","order_by":24,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":657480,"visible":true,"origin":"","legend":"","description":"","filename":"Figure14.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/a571f4e28f443917481f8e09.tif"},{"id":94024129,"identity":"96335adf-1a7c-467c-83dd-73481131cce5","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"tif","order_by":25,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":246780,"visible":true,"origin":"","legend":"","description":"","filename":"Figure2.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/707f650bb4a8d0c29db9aead.tif"},{"id":94024130,"identity":"cb36e6e9-4524-4a38-ae3a-06776b19001f","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"tif","order_by":26,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1948004,"visible":true,"origin":"","legend":"","description":"","filename":"Figure3.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/3fc3a38c69fb77a62720a7b9.tif"},{"id":94024125,"identity":"53f51ecf-a76f-4132-bba9-afe15a486444","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"tif","order_by":27,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":226620,"visible":true,"origin":"","legend":"","description":"","filename":"Figure4.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/45df06241ebe59f24799c2f9.tif"},{"id":94024139,"identity":"adaf725c-7363-4cbd-bf18-58a18b1c0075","added_by":"auto","created_at":"2025-10-21 13:02:45","extension":"tif","order_by":28,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1033652,"visible":true,"origin":"","legend":"","description":"","filename":"Figure5.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/7b4da61928a1f1930da314df.tif"},{"id":94026027,"identity":"92d9e17c-532a-4d93-bd6f-d60da0f020a8","added_by":"auto","created_at":"2025-10-21 13:26:45","extension":"tif","order_by":29,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":2448780,"visible":true,"origin":"","legend":"","description":"","filename":"Figure6.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/fb92480a27a08b5e826e0db0.tif"},{"id":94024134,"identity":"96f3366a-f097-430c-a9c0-e0f6f1606dbe","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"tif","order_by":30,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1315416,"visible":true,"origin":"","legend":"","description":"","filename":"Figure7.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/c5a3dfd9ab688b254a09cad9.tif"},{"id":94024738,"identity":"ce2508c1-13b4-413c-9469-0ef36761abe5","added_by":"auto","created_at":"2025-10-21 13:10:45","extension":"tif","order_by":31,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":118012,"visible":true,"origin":"","legend":"","description":"","filename":"Figure8.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/cf3cadb2b5a4f7f26c8aaba4.tif"},{"id":94024735,"identity":"bc1fdc35-dd44-4835-955b-ac025528e639","added_by":"auto","created_at":"2025-10-21 13:10:45","extension":"tif","order_by":32,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1674180,"visible":true,"origin":"","legend":"","description":"","filename":"Figure9.tif","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/ecfe26cba43bc66adc2c316f.tif"},{"id":94024739,"identity":"8e77903b-5d48-4496-bd14-50e6172d25e1","added_by":"auto","created_at":"2025-10-21 13:10:45","extension":"png","order_by":33,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":978389,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure1.png","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/8592be64d5f14d2979356d12.png"},{"id":94024153,"identity":"96dc502c-df5d-4d5d-b04c-3ea2a5cf5e01","added_by":"auto","created_at":"2025-10-21 13:02:45","extension":"png","order_by":34,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":414485,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure10.png","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/59f5ff5894c577bf9b27c74b.png"},{"id":94024147,"identity":"4dfe2c00-9cda-41bb-ad53-a034a28a5323","added_by":"auto","created_at":"2025-10-21 13:02:45","extension":"png","order_by":35,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":150185,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure11.png","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/c069db43c0bf11c8d5435815.png"},{"id":94024745,"identity":"9e311d0d-0ca5-44d8-bf66-b86f97568ff8","added_by":"auto","created_at":"2025-10-21 13:10:45","extension":"png","order_by":36,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1479929,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure12.png","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/4fc96333cf09f49de76c05c5.png"},{"id":94025129,"identity":"2aa763f1-44a1-4502-9368-c167bd0db05b","added_by":"auto","created_at":"2025-10-21 13:18:45","extension":"png","order_by":37,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":653140,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure13.png","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/bfe09906f367cd4dd377eb64.png"},{"id":94024140,"identity":"93ea2d3b-8354-4da0-88c8-5172ad52a559","added_by":"auto","created_at":"2025-10-21 13:02:45","extension":"png","order_by":38,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":44699,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure14.png","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/8631149c3bc26e194316fca2.png"},{"id":94025126,"identity":"5279f9fd-5f46-4918-ad72-745b60ebcc50","added_by":"auto","created_at":"2025-10-21 13:18:45","extension":"png","order_by":39,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":18655,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure2.png","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/656d1ec5a1c873e4f2e60b48.png"},{"id":94024146,"identity":"859d7839-d18a-4334-b622-fbf732fd7156","added_by":"auto","created_at":"2025-10-21 13:02:45","extension":"png","order_by":40,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1112131,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure3.png","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/80b283ddd10e931398f0975c.png"},{"id":94024143,"identity":"083cc511-7972-4aeb-a9f3-1504b080cbcf","added_by":"auto","created_at":"2025-10-21 13:02:45","extension":"png","order_by":41,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":81095,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure4.png","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/1a0bce66dd5faffc527544ea.png"},{"id":94024743,"identity":"d0138b99-b185-4d13-a6f7-33b17e16fa36","added_by":"auto","created_at":"2025-10-21 13:10:45","extension":"png","order_by":42,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":315428,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure5.png","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/67ab59c773fd3a989dd987a7.png"},{"id":94024157,"identity":"18f8ceeb-985f-48de-8658-0b003453db44","added_by":"auto","created_at":"2025-10-21 13:02:45","extension":"png","order_by":43,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1316127,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure6.png","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/100df11935e72453d0600762.png"},{"id":94024151,"identity":"6ee66071-c213-46ed-beeb-3c8144a26180","added_by":"auto","created_at":"2025-10-21 13:02:45","extension":"png","order_by":44,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":623955,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure7.png","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/24f0ce765ee421db78b412f1.png"},{"id":94024160,"identity":"74055660-c969-4436-b3b4-d9e6f954b7e9","added_by":"auto","created_at":"2025-10-21 13:02:50","extension":"png","order_by":45,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":9331,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure8.png","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/1e957a7c86ae282ef7a85091.png"},{"id":94024744,"identity":"b1fb049e-a8e9-46cd-a3ef-73702d69eaf4","added_by":"auto","created_at":"2025-10-21 13:10:45","extension":"png","order_by":46,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":870625,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure9.png","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/38fccb2c1526887e6119f1d1.png"},{"id":94026029,"identity":"70902b98-ae31-4b28-a490-36188c2ccb48","added_by":"auto","created_at":"2025-10-21 13:26:45","extension":"xml","order_by":47,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":143047,"visible":true,"origin":"","legend":"","description":"","filename":"14390bc92f794bbd88524f7f14c2273a1structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/7a269897a161ab48a53aa1e1.xml"},{"id":94024156,"identity":"8fbdaaa4-17ee-44c9-a567-b4dda50b27aa","added_by":"auto","created_at":"2025-10-21 13:02:45","extension":"html","order_by":48,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":157354,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/541ae59d25546f9c1c6ac448.html"},{"id":94024161,"identity":"44101dc2-4418-4738-9528-2650bff8712b","added_by":"auto","created_at":"2025-10-21 13:02:51","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":672819,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eFlow Chart of Network Pharmacology and Molecular Docking.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure1.tif.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/2f0995fa06cf28e1c0f14c48.jpg"},{"id":94024097,"identity":"bed4f43b-5b70-42e6-8cbb-2e6ca179dffd","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":98106,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eThe Venn diagram of related targets between Sal and ALI.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure2.tif.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/2ddb2429a618cc7fbe43ee27.jpg"},{"id":94024096,"identity":"f7867d82-48ba-446b-addf-7d2149c3d5c4","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":602925,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eProtein-protein interaction network diagram and Core Genes Acquisition. A: Protein-protein interaction network diagram; B: Core Genes.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure3.tif.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/b634268012214380d4eb0b19.jpg"},{"id":94025121,"identity":"f7962cc0-8243-4070-87eb-6255ba2a5032","added_by":"auto","created_at":"2025-10-21 13:18:44","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":1240491,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eGO enrichment analysis.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure4.tif.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/735950dffa9615a62a11e253.jpg"},{"id":94024099,"identity":"dda355b4-8c99-4def-bb8d-e2f7fb390208","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"jpg","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":2186961,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eKEGG enrichment analysis.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure5.tif.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/a25bf0268905156b67b83e95.jpg"},{"id":94024719,"identity":"506ee077-4b47-47ff-ab41-fca880cea07b","added_by":"auto","created_at":"2025-10-21 13:10:44","extension":"jpg","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":490675,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMolecular Docking. A: Salidroside with MAPK14; B: Salidroside with GPX4.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure6.tif.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/b052e4d9e9d944addf14d465.jpg"},{"id":94024720,"identity":"1b20edc7-087f-4304-ad6c-19c090931ea4","added_by":"auto","created_at":"2025-10-21 13:10:44","extension":"jpg","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":374092,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eCell experiment flowchart.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure7.tif.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/2b20f169db28140824db98a0.jpg"},{"id":94024722,"identity":"a70d8f64-b5af-4c1b-bd30-e0dce576bc55","added_by":"auto","created_at":"2025-10-21 13:10:44","extension":"jpg","order_by":8,"title":"Figure 8","display":"","copyAsset":false,"role":"figure","size":168622,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eChanges in proliferation rate of RLE-6TN cells treated with Sal. \u003c/strong\u003e\u003csup\u003e\u003cstrong\u003e##\u003c/strong\u003e\u003c/sup\u003e\u003cem\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e\u0026lt;0.01 VS Control group; \u003c/strong\u003e\u003csup\u003e\u003cstrong\u003e*\u003c/strong\u003e\u003c/sup\u003e\u003cem\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e\u0026lt;0.05 VS LPS group; Mean ± SD, n=3.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure8.tif.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/a28bee4ee4b69bf02d6e9607.jpg"},{"id":94024112,"identity":"9c80b5bf-ddce-45b1-a96a-1474a7f9132e","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"jpg","order_by":9,"title":"Figure 9","display":"","copyAsset":false,"role":"figure","size":675831,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eChanges in apoptosis rate of RLE-6TN cells treated with Sal. \u003c/strong\u003e\u003csup\u003e\u003cstrong\u003e##\u003c/strong\u003e\u003c/sup\u003e\u003cem\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e\u0026lt;0.01 VS Control group; \u003c/strong\u003e\u003csup\u003e\u003cstrong\u003e*\u003c/strong\u003e\u003c/sup\u003e\u003cem\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e\u0026lt;0.05 VS LPS group; Mean ± SD, n=3.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure9.tif.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/d78a8e98821fc2f07b7fcfae.jpg"},{"id":94025123,"identity":"650ede24-3314-42fc-b970-ffbfb67b2db9","added_by":"auto","created_at":"2025-10-21 13:18:44","extension":"jpg","order_by":10,"title":"Figure 10","display":"","copyAsset":false,"role":"figure","size":350311,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eChanges in ROS content in RLE-6TN cells treated with Sal. \u003c/strong\u003e\u003csup\u003e\u003cstrong\u003e##\u003c/strong\u003e\u003c/sup\u003e\u003cem\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e\u0026lt;0.01 VS Control group; \u003c/strong\u003e\u003csup\u003e\u003cstrong\u003e*\u003c/strong\u003e\u003c/sup\u003e\u003cem\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e\u0026lt;0.05 VS LPS group; Mean ± SD, n=3.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure10.tif.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/4e0b954341bdd0ed90c0c500.jpg"},{"id":94024101,"identity":"73d8317a-e6af-4860-bc9c-0ba4c2b270de","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"jpg","order_by":11,"title":"Figure 11","display":"","copyAsset":false,"role":"figure","size":80528,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eChanges in Fe\u003c/strong\u003e\u003csup\u003e\u003cstrong\u003e2+\u003c/strong\u003e\u003c/sup\u003e\u003cstrong\u003e and MDA content in RLE-6TN cells treated with Sal. A: Changes in Fe\u003c/strong\u003e\u003csup\u003e\u003cstrong\u003e2+\u003c/strong\u003e\u003c/sup\u003e\u003cstrong\u003e content, B: Changes in MDA content; \u003c/strong\u003e\u003csup\u003e\u003cstrong\u003e##\u003c/strong\u003e\u003c/sup\u003e\u003cem\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e\u0026lt;0.01 VS Control group, \u003c/strong\u003e\u003csup\u003e\u003cstrong\u003e**\u003c/strong\u003e\u003c/sup\u003e\u003cem\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e\u0026lt;0.01 VS LPS group; Mean ± SD, n=3.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure11.tif.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/3c0cb3bd379f497d619ae472.jpg"},{"id":94024725,"identity":"05ccf274-a421-4631-ae9b-3c1039a6f7bc","added_by":"auto","created_at":"2025-10-21 13:10:44","extension":"jpg","order_by":12,"title":"Figure 12","display":"","copyAsset":false,"role":"figure","size":637630,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eChanges in immunofluorescence intensity of GPX4 in RLE-6TN cells treated with Sal. n=3.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure12.tif.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/bac59c46e2371012ffe54d98.jpg"},{"id":94024110,"identity":"e65c2a3b-147a-4e97-bb7e-152be1d0b0fe","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"jpg","order_by":13,"title":"Figure 13","display":"","copyAsset":false,"role":"figure","size":310754,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eWestern blot was used to detect the protein expression of GPX4、gp130、IL-6、MAPK and p-MAPK in cells.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure13.tif.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/b73b3971f82a28e6d1a67e90.jpg"},{"id":94024120,"identity":"91393f0a-ef2d-4049-ba61-3794b6562a25","added_by":"auto","created_at":"2025-10-21 13:02:44","extension":"jpg","order_by":14,"title":"Figure 14","display":"","copyAsset":false,"role":"figure","size":147756,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSchematic of the protective mechanism of Sal against LPS-induced ALI. Sal inhibits the IL-6-gp130 interaction, thereby suppressing the MAPK/GPX4 pathway. This leads to the downregulation of ROS, MDA, and Fe²⁺, ultimately inhibiting ferroptosis in alveolar epithelial cells.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure14.tif.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/484d887a8884610a37c401d1.jpg"},{"id":102234074,"identity":"0f2805a1-7d71-49a0-8f85-0c6b8fd81d88","added_by":"auto","created_at":"2026-02-09 16:05:38","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":10084493,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/4ab0d2bc-57ed-482c-a1d1-41e50dbe4e76.pdf"},{"id":94025120,"identity":"f966678c-5b4f-4f12-a85f-754cfd6db1c5","added_by":"auto","created_at":"2025-10-21 13:18:44","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":215925,"visible":true,"origin":"","legend":"","description":"","filename":"supplementaryfile.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7610425/v1/f8913665ac9947a731d84286.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Combining Network Pharmacology and Experimental Validation to Demonstrate That Salidroside Alleviates Acute Lung Injury by Inhibiting Ferroptosis via the MAPK/GPX4 Pathway","fulltext":[{"header":"Introduction","content":"\u003cp\u003eAcute lung injury (ALI) and its most severe form, acute respiratory distress syndrome (ARDS), are life-threatening conditions characterized by widespread diffuse damage to alveolar epithelial cells (AECII) and uncontrolled inflammation. These conditions manifest as bilateral pulmonary opacities on imaging accompanied by severe hypoxemia(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e). The underlying mechanisms are highly complex, involving an imbalance in inflammatory responses, regulation of aquaporins, dysregulation of coagulation/fibrinolysis systems, apoptosis, autophagy, fever, among others(\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e). Despite significant efforts directed towards the immune response against infections\u0026mdash;exacerbated by the emergence of novel pathogens such as the global pandemic of COVID-19(\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e), and the ongoing rise in drug resistance, effective pharmacological therapies for ALI remain elusive(\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e). Increasing evidence suggests that acute lung injury is closely associated with non-apoptotic pathways including pyroptosis(\u003cspan additionalcitationids=\"CR8\" citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e)and ferroptosis(\u003cspan additionalcitationids=\"CR11\" citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e). Ferroptosis is a recently identified form of regulated cell death distinct from necrosis and apoptosis; it is characterized by iron-dependent accumulation of lipid peroxides (LPO)(\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e)and manifests through decreased activity of key antioxidant enzymes such as GPX4 within the glutathione system(\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e). Iron deposition has been observed in the lower respiratory tract of ALI patients; this accumulation can lead to inflammatory responses, oxidative stress, and mitochondrial dysfunction which further exacerbate lung injury severity(\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e). A deeper understanding of the molecular mechanisms underlying ferroptosis in ALI may provide new therapeutic avenues for treating acute lung injury.\u003c/p\u003e\u003cp\u003ePrevious studies have indicated that traditional Chinese medicine exhibits therapeutic effects on sepsis-induced acute lung injury(\u003cspan additionalcitationids=\"CR17\" citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e). Salidroside is a bioactive component derived from Rhodiola rosea. Its antioxidative properties(\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e), anti-aging effects(\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e), anticancer activities(\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e), and immunomodulatory functions(\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e)have been widely validated. Our prior research demonstrated that salidroside could prevent sepsis-related acute lung injury while reducing pro-inflammatory cytokine production(\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e), highlighting its potential clinical value.\u003c/p\u003e\u003cp\u003eNetwork pharmacology offers insights into disease pathogenesis and progression from a systems biology perspective; it can elucidate the actions of traditional Chinese medicines(\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e). Molecular docking serves as a computational method to assess binding affinities between small molecules and specific receptors through active component screening(\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e). Therefore, we employed network pharmacology alongside molecular docking techniques to uncover the mechanistic pathways through which salidroside exerts its therapeutic effects on ALI. Finally, we conducted further validation at the cellular level regarding both efficacy and mechanism.\u003c/p\u003e"},{"header":"Materials and Methods","content":"\u003cp\u003e\u003cstrong\u003e1.1 Network Pharmacology and Molecular Docking\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e1.11 Target Identification for Salidroside\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe compound Salidroside was input into the PubChem database (https://pubchem.ncbi.nlm.nih.gov/)(26)to obtain its SMILES identifier. Subsequently, this identifier was entered into the SwissTargetPrediction database (http://www.swisstargetprediction.ch/)(27), where targets with a Probability \u0026gt; 0 were selected, along with data from the CHEMBL database (https://www.ebi.ac.uk/chembl/)(28)and Super-PRED database (https://prediction.charite.de)(29). The species filter was restricted to \u0026quot;Homo sapiens\u0026quot;. Target proteins were standardized using the UniProt database (https://www.uniprot.org). After integrating prediction results and removing duplicates, a final list of target genes for Rhodiola rosea glycoside was compiled(30).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e1.12 Acquisition of Acute Lung Injury Targets\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTargets associated with acute lung injury were primarily sourced from GeneCards (https://www.genecards.org/)(31), OMIM (https://www.omim.org/)(32)and CTD databases (https://ctdbase.org)(33)，by searching for the keyword \u0026quot;acute lung injury\u0026quot; .Following integration and removal of duplicate target genes across these three databases, a set of disease-specific target genes related to acute lung injury was obtained.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e1.13 Core Gene Identification\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eVenny 2.1 online software tool (https://bioinfogp.cnb.csic.es/tools/venny/) was utilized to analyze common action targets between Rhodiola rosea glycoside and acute lung injury in order to identify shared drug-disease targets. A protein-protein interaction network diagram was constructed using the STRING online platform (https://string-db.org/)(34)with species limited to \u0026quot;Homo sapiens\u0026quot; and a confidence score set at \u0026ge; 0.9. This network data was then imported into Cytoscape 3.8.2, where core genes were ranked based on values assigned through topological network algorithms via the cytoHubba plugin for further exploration and analysis of core gene networks.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e1.14 GO and KEGG Pathway Enrichment Analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTo further investigate the mechanism of Rhodiola rosea glycoside in treating acute lung injury (ALI), core genes were submitted to the DAVID database (https://david.ncifcrf.gov/)(35)for Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. The GO enrichment analysis was visualized using bubble plots that display the top ten biological processes, cellular components, and molecular functions, while a bar chart illustrated the top twenty KEGG pathways.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e1.15 Molecular Docking\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe structure of Rhodiola rosea glycoside was obtained from the PubChem database, converted into a three-dimensional format, and saved in *MOL format. AutoDock version 1.5.6 was used to process this structure, saving it as a *PDBQT file. The crystal structure of the target protein was retrieved from the PDB database (http://www.RLsb.org). PyMol and AutoDock software were employed to manipulate the target protein molecule, which was also saved in *PDBQT format. Using AutoDock-Vina, molecular docking between Rhodiola rosea glycoside and the target protein was performed; results were visualized using PyMol version 1.7.x.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e1.2 Cell Experiments\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e1.21 Cells and reagents\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRat alveolar type II epithelial cells (RLE-6TN) were purchased from Hunan Fenghui Biotechnology Co., Ltd.; CCK-8 assay kit (Lot: C0038) was obtained from Shanghai Biyuntian Biotechnology Co., Ltd.; ANNEXIN V-FITC/PI apoptosis detection kit (Lot: CA1020) was sourced from Beijing Solarbio Technology Co., Ltd.; H2DCFDA (Synonyms: DCFH-DA; 2\u0026apos;,7\u0026apos;-Dichlorodihydrofluorescein diacetate) (Lot: 4091990) was acquired from MedChemExpress in the USA; Fe2+ ELISA kit (Lot: BC5415) was purchased from Beijing Solarbio Technology Co., Ltd.; MDA ELISA kit (Lot: S0131S) was obtained from Shanghai Biyuntian Biotechnology Co., Ltd.; TBST wash buffer was sourced from Beijing Solarbio Technology Co., Ltd.; antibody dilution buffer and 5% BSA blocking solution were both purchased from Beijing Zhongshu Jinqiao Biotechnology Co., Ltd. The GPX4 Monoclonal antibody (Lot: 67763-1-Ig, dilution ratio 1:5000 for a molecular weight of 20 kDa) was acquired from Proteintech in the USA; Anti-CD130 (gp130) antibody [EPR24557-50] (Lot: ab283685, dilution ratio 1:1000 for a molecular weight of 130 kDa), Anti-IL-6 antibody [EPR23819-103] (Lot: ab290735, dilution ratio 1:1000 for a molecular weight of 23 kDa), and Anti-p38 phospho T180 + Y182 antibody(Lot: ab4822, dilution ratio 1:1000 for a molecular weight of 38 kDa) were all sourced from Abcam in the UK. The p38 MAPK Polyclonal antibody (Lot：14064-1-AP，dilution ratio：1：5000，molecular weight：38 kDa) was obtained from Proteintech in the USA; Beta Actin Monoclonal antibody (Lot：29380-1-AP，dilution ratio：1：5000，molecular weight：42 kDa）was also acquired from Proteintech; Goat Anti-Mouse IgG/HRP（Lot：SE131，dilution ratio：1：2000）was purchased from Beijing Solarbio Technology Co., Ltd.; Goat Anti-Rabbit IgG H\u0026amp;L (HRP) (Lot : ab6721 , dilution rate : 1 :2000 ) came from Abcam Limited in the UK.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e1.22 Cell culture\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eCell Culture Rat alveolar type II epithelial cells (RLE-6TN) were cultured using DMEM complete medium, which was prepared by adding 10% fetal bovine serum and 1% antibiotics. Both cell lines were placed in an incubator containing 95% O2 and 5% CO2, maintained at a constant temperature of 37\u0026deg;C. Once the cells reached approximately 90% confluence, they were digested for passage using 0.25% trypsin, with logarithmic phase cells being used for experimental procedures.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e1.23 Cell proliferation detection\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eCCK-8 Assay for Cell Proliferation RLE-6TN cells were seeded in a 96-well plate, with a total volume of culture medium per well set to 200 \u0026mu;l. The groups included: culture medium group containing cells (control group), LPS group (5 \u0026mu;g/ml), and LPS+Sal group (40 \u0026mu;g/ml). After drug treatment for eight hours, CCK-8 reagent (20 \u0026mu;l) was added to each well, followed by incubation in the incubator for an additional period of one to four hours until the color developed into deep brown. Subsequently, the optical density (OD) value of each well was measured at a wavelength of 450 nm using a microplate reader. The percentage of cell proliferation was calculated as follows: Cell proliferation percentage = [(Experimental Group OD - Blank Group OD) / (Control Group OD - Blank Group OD)] \u0026times;100%.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e1.24 Cell apoptosis detection\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eFlow Cytometry Detection of Apoptosis After appropriate culture stimulation, all cells along with their culture medium were transferred into centrifuge tubes and centrifuged at room temperature at 1000 rpm for five minutes to remove the supernatant. Cells were then resuspended in PBS solution (3 ml), followed by another round of centrifugation under the same conditions; this step was repeated twice more before resuspending the final pellet in binding buffer solution while removing excess supernatant after each spin cycle. For staining, each sample received a mixture consisting of 100 \u0026mu;l binding buffer along with Annexin V and PI staining solution (5 \u0026mu;l each). The samples were gently mixed and incubated at room temperature away from light for fifteen minutes before undergoing another centrifugation step at room temperature at 1000 rpm for five minutes to discard supernatants again; finally, they were resuspended in PBS solution prior to immediate analysis via flow cytometry.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e1.25 ROS detection\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eFlow Cytometry Detection of ROS Concentration A stock solution comprising H2DCFDA dissolved in DMSO was prepared by dissolving five milligrams into one point zero three milliliters DMSO as needed; subsequently diluted with pre-warmed serum-free cell culture media or PBS to achieve working concentrations ranging from five to ten micromolar H2DCFDA solutions according to manufacturer instructions.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e1.26 ELISA detection of Fe\u003csup\u003e2+\u003c/sup\u003e and MDA\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eELISA Detection of Fe\u003csup\u003e2+\u003c/sup\u003e and MDA Concentrations Cell supernatants were collected, and the concentrations of Fe\u003csup\u003e2+\u003c/sup\u003e and MDA were measured according to the instructions provided in the Fe\u003csup\u003e2+\u003c/sup\u003e and MDA ELISA kit. The optical density values for each well were determined using a microplate reader at a wavelength of 450 nm.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e1.27 Immunofluorescence detection of GPX4\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eImmunofluorescence Detection of GPX4 Concentration To assess the protein levels of glutathione peroxidase 4 (GPX4) in cells, treated RLE-6TN cells were seeded onto glass-bottom culture dishes. After treatment, cells were fixed with 4% paraformaldehyde at room temperature for 15 minutes, followed by permeabilization with 0.1% Triton X-100 for 10 minutes. Subsequently, cells were blocked in PBS containing 5% bovine serum albumin at room temperature for one hour. Cells were then incubated overnight at 4 \u0026deg;C with a primary antibody specific to GPX4. Following PBS washes, cells were incubated in the dark at room temperature for one hour with an Alexa Fluor 488-conjugated goat anti-rabbit IgG secondary antibody. The cell nuclei were counterstained with DAPI (1 \u0026mu;g/mL) for five minutes. Finally, samples were mounted using an anti-fade mounting medium. All images from samples were acquired using a microscope model such as Nikon A1R+ laser confocal microscope under a \u0026times;60 oil immersion objective lens to ensure reliable comparisons of fluorescence intensity; all experimental groups and control groups underwent staining within the same batch while utilizing identical microscopy parameters during image acquisition.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e1.28 Western blot\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eProtein Immunoblotting Analysis Cell samples from four different groups were collected and lysed using RIPA buffer supplemented with PMSF (100 mM) in a ratio of 100 \u0026micro;L RIPA + 1 \u0026micro;L PMSF by pipetting gently before placing on ice for thirty minutes post-lysis; subsequently centrifuged at 12,000 rpm for thirty minutes at 4\u0026deg;C after lysis completion. Protein concentration was quantified using BCA assay kits following their operational protocols. For protein blotting analysis, BeyoECL Plus reagent kit (P0018S; Beyotime, China) was employed along with imaging performed via Tanon Imaging System (Tanon, China).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e2. Statistical analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe results are expressed as mean \u0026plusmn; SD. Use unpaired two-sided student t-tests for two group comparisons or one-way ANOVA tests, and then use Bonferroni post hoc tests for multiple comparisons to analyze differences. \u003cem\u003eP\u003c/em\u003e\u0026lt;0.05 is considered to indicate significant statistical differences.\u0026nbsp;\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003e\u003cstrong\u003e3.1 Network Pharmacology and Molecular Docking Results\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe results of network pharmacology and molecular docking indicate that Salidroside exerts its therapeutic effects on acute lung injury (ALI) through a synergistic action involving multiple targets and pathways. The flowchart is illustrated in Figure 1.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 1. Flow Chart of Network Pharmacology and Molecular Docking.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.11 Intersection Genes between Salidroside and Acute Lung Injury\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIn this study, we identified 382 targets associated with Salidroside from the ChEMBL, Swiss TargetPrediction, and Super-PRED databases. Subsequently, we determined 11,036 targets closely related to ALI using the GeneCards, OMIM, and CTD databases. Through Venn diagram analysis, we obtained a set of 355 overlapping targets as potential candidates for Salidroside treatment of ALI (Figure 2).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 2. The Venn diagram of related targets between Sal and ALI.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.12 Protein Interaction Network Diagram and Core Genes Acquisition\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;Using the STRING database along with Cytoscape software, we constructed a protein-protein interaction network diagram for detailed analysis to gain insights into the topological features of these nodes. This visualization effectively conveys the significance of each node through size and color; it includes 213 nodes and 470 edges where larger nodes with darker colors represent higher degree values within the network (Figure 3A). Further analysis utilizing the cytoHubba plugin in Cytoscape allowed us to identify 20 key targets involved in Salidroside\u0026apos;s treatment of ALI (Figure 3B).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 3. Protein-protein interaction network diagram and Core Genes Acquisition. A: Protein-protein interaction network diagram; B: Core Genes.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.13 GO and KEGG Pathway Analysis for Sal Treatment in ALI\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe top twenty key genes were imported into the DAVID database for Gene Ontology (GO) enrichment analysis as well as KEGG pathway enrichment analysis. The GO enrichment results indicated involvement in 190 biological processes, 28 cellular components, and 44 molecular functions. We selected the top ten entries from each category which are visually represented in an enrichment chart (Figure 4), providing a clear overview related to Salidroside\u0026rsquo;s therapeutic effects on ALI\u0026mdash;primarily concerning signal transduction, cytosol localization, protein binding among others. The KEGG pathway enrichment analysis revealed associations with151 signaling pathways predominantly linked to MAPK signaling pathway and VEGF signaling pathway; details regarding the top twenty results are shown in Figure5.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003e4.\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003eGO enrichment analysis\u003c/strong\u003e\u003cstrong\u003e.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 5. KEGG enrichment analysis.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.14 Molecular Docking\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMolecular docking analysis was conducted between Sal and two genes related to the study, MAPK14 and GPX4. The results highlighted the strong binding affinity of Sal to these key proteins (Table 1). To further elucidate the complex binding configurations, we utilized PyMOL for visualization, displaying the lowest energy binding conformation (Figure 6). This visualization vividly illustrates the close relationship between Sal and its critical targets, providing valuable insights into their interaction\u0026apos;s structural basis and reinforcing the significance of Sal in treating ALI at a molecular level.\u003c/p\u003e\n\u003cp\u003eTable 1. Verification results of molecular docking\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 114px;\"\u003e\n \u003cp\u003eIngredients\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 114px;\"\u003e\n \u003cp\u003etargets\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 114px;\"\u003e\n \u003cp\u003eAffifinity (kcal/mol)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 227px;\"\u003e\n \u003cp\u003eDistance from best mode\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003ermsd l.b.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003ermsd u.b.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 114px;\"\u003e\n \u003cp\u003eSalidroside\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003eMAPK14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003e- 6.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003eGPX4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003e- 6.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 6. Molecular Docking. A: Salidroside with MAPK14; B: Salidroside with GPX4.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.2 Cellular Experimental Results\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAcute lung injury caused by septic infection leads to widespread diffuse damage and uncontrolled inflammation in alveolar epithelial cells. Therefore, this study selected rat alveolar type II epithelial cells for subsequent research; the flowchart is shown in Figure 7.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 7. Cell experiment flowchart.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.21 Cell Proliferation Assay\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe proliferation of cells from different groups was assessed using a CCK-8 kit, as illustrated in Figure 8. The cell proliferation rate in the LPS group was significantly lower than that of the control group (\u003cem\u003eP\u003c/em\u003e\u0026lt;0.01); however, upon addition of Sal, there was an increase in cell proliferation rate compared to the LPS group (\u003cem\u003eP\u003c/em\u003e\u0026lt;0.05). This suggests that Sal can mitigate LPS-induced cytotoxicity and enhance cell viability.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 8. Changes in proliferation rate of RLE-6TN cells treated with Sal. \u003csup\u003e##\u003c/sup\u003e\u003cem\u003eP\u003c/em\u003e\u0026lt;0.01 VS Control group; \u003csup\u003e*\u003c/sup\u003e\u003cem\u003eP\u003c/em\u003e\u0026lt;0.05 VS LPS group; Mean \u0026plusmn; SD, n=3.\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.22 Cell Apoptosis Assay\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAs depicted in Figure 9, apoptosis detection across different groups revealed that the apoptosis rate in the LPS group was significantly higher than that of the control group (\u003cem\u003eP\u003c/em\u003e\u0026lt;0.01); following treatment with Sal, there was a decrease in apoptosis rate compared to the LPS group (P\u0026lt;0.05). This indicates that Sal may inhibit LPS-induced apoptosis and improve cell viability.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 9. Changes in apoptosis rate of RLE-6TN cells treated with Sal. \u003csup\u003e##\u003c/sup\u003e\u003cem\u003eP\u003c/em\u003e\u0026lt;0.01 VS Control group; \u003csup\u003e*\u003c/sup\u003e\u003cem\u003eP\u003c/em\u003e\u0026lt;0.05 VS LPS group; Mean \u0026plusmn; SD, n=3.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.33 ROS Detection\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eROS levels were measured using an ROS detection kit across various groups as shown in Figure 10; it was found that ROS content in the LPS group was significantly higher than that of controls (\u003cem\u003eP\u003c/em\u003e\u0026lt;0.01). After adding Sal, ROS levels decreased compared to those observed with LPS alone (\u003cem\u003eP\u003c/em\u003e\u0026lt;0.05), suggesting that Sal can suppress oxidative stress induced by LPS on cells.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 10. Changes in ROS content in RLE-6TN cells treated with Sal. \u003csup\u003e##\u003c/sup\u003e\u003cem\u003eP\u003c/em\u003e\u0026lt;0.01 VS Control group; \u003csup\u003e*\u003c/sup\u003e\u003cem\u003eP\u003c/em\u003e\u0026lt;0.05 VS LPS group; Mean \u0026plusmn; SD, n=3.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.34 ELISA Detection of Fe\u003csup\u003e2+\u003c/sup\u003e and MDA\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAs presented in Figure 11, both Fe\u003csup\u003e2+\u003c/sup\u003e and MDA levels were significantly elevated in comparison with controls within the LPS group (\u003cem\u003eP\u003c/em\u003e\u0026lt;0.01); conversely, Fe\u003csup\u003e2+\u003c/sup\u003e and MDA concentrations were markedly reduced after treatment with Sal when compared to those seen with just LPS exposure (\u003cem\u003eP\u003c/em\u003e\u0026lt;0.01). These findings indicate that Sal may inhibit iron death and lipid peroxidation triggered by LPS.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 11. Changes in Fe\u003csup\u003e2+\u003c/sup\u003e and MDA content in RLE-6TN cells treated with Sal. A: Changes in Fe\u003csup\u003e2+\u003c/sup\u003e content, B: Changes in MDA content; \u003csup\u003e##\u003c/sup\u003e\u003cem\u003eP\u003c/em\u003e\u0026lt;0.01 VS Control group, \u003csup\u003e**\u003c/sup\u003e\u003cem\u003eP\u003c/em\u003e\u0026lt;0.01 VS LPS group; Mean \u0026plusmn; SD, n=3.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.35 Immunofluorescence Detection of GPX4\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTo verify changes regarding GPX4 among different cellular groups, immunofluorescence detection for GPX4 was performed as illustrated in Figure 12; it showed significant reductions in immunofluorescence intensity for GPX4 within samples fromtheL PSgroup relative to controls; however ,followingSal treatment ,GPX4 immunofluorescence intensity increased substantially when comparedtoL PSalone .\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 12. Changes in immunofluorescence intensity of GPX4 in RLE-6TN cells treated with Sal. n=3.\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.36 Western Blot\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTo elucidate the associated pathways, we conducted Western blot analysis on GPX4, gp130, IL-6, MAPK, and p-MAPK. As illustrated in Figure 13, compared to the control group, the LPS group exhibited significantly elevated levels of gp130, IL-6, and p-MAPK (\u003cem\u003eP\u003c/em\u003e\u0026lt;0.01). Following the administration of Sal, there was a notable decrease in the levels of gp130, IL-6, and p-MAPK when compared to the LPS group (\u003cem\u003eP\u003c/em\u003e\u0026lt;0.01). Conversely, while GPX4 levels were significantly reduced in the LPS group relative to the control group (\u003cem\u003eP\u003c/em\u003e\u0026lt;0.01), a marked increase in GPX4 was observed in the Sal group compared to the LPS group (\u003cem\u003eP\u003c/em\u003e\u0026lt;0.01). These findings suggest that Sal may mitigate lung injury by modulating the MAPK/GPX4 pathway.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 13. Western blot was used to detect the protein expression of GPX4\u003c/strong\u003e\u003cstrong\u003e、\u003c/strong\u003e\u003cstrong\u003egp130\u003c/strong\u003e\u003cstrong\u003e、\u003c/strong\u003e\u003cstrong\u003eIL-6\u003c/strong\u003e\u003cstrong\u003e、\u003c/strong\u003e\u003cstrong\u003eMAPK and p-MAPK in cells.\u003c/strong\u003e\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eAcute lung injury arises from widespread damage to the pulmonary microvascular endothelium and alveolar epithelium triggered by severe infection, shock, trauma or burns. Clinically it manifests as diffuse interstitial and alveolar oedema culminating in acute hypoxaemic respiratory insufficiency that can progress to life-threatening ARDS(36-38). To date, no pharmacological agent has been approved specifically for ALI, and off-label therapies frequently provoke coagulopathy, gastric ulceration or osteoporosis(39). By contrast, syndrome-based Chinese medicine employs either purified herbal monomers or multi-compound formulae to prevent or treat ALI/ARDS with encouraging results(40). Salidroside, the principal bioactive constituent of Rhodiola rosea, has been reported to attenuate ALI through antioxidant and anti-inflammatory actions(23, 41, 42); nevertheless, the precise molecular circuitry remains ill-defined. Here we integrated network pharmacology with molecular docking to map the therapeutic interactome of salidroside in ALI and subsequently validated the predictions experimentally in vitro. Our data demonstrate that (1) salidroside exerts protective effects against ALI via a multi-target, multi-pathway mechanism, and (2) salidroside suppresses LPS-evoked accumulation of ROS, Fe\u0026sup2;⁺, MDA and IL-6, dampens p-MAPK signalling, while restoring GPX4 expression.\u003c/p\u003e\n\u003cp\u003eGO enrichment analysis revealed that ALI-relevant biological processes are enriched in signal transduction and protein phosphorylation. At the cellular-compartment level, salidroside preferentially modulates proteins localized to the cytoplasm and nucleus. Molecular-function profiling further indicated that ALI perturbs both protein-binding and ATP-binding capacities. KEGG pathway mapping identified MAPK, mTOR and VEGF cascades as the most significantly represented signalling routes\u0026mdash;networks intimately linked to cell proliferation, differentiation, apoptosis and immune\u0026ndash;inflammatory responses\u0026mdash;thereby positioning salidroside as a promising botanical monomer for ALI prophylaxis and therapy. Independent studies corroborate these in silico predictions. Guo et al.(41)reported that salidroside suppresses hyperoxia-induced AECⅡ ferroptosis via blockade of the p38 MAPK axis, reversing hyperoxic lung injury in neonatal rats. Similarly, in LPS-challenged rodents, salidroside down-regulated p38 MAPK phosphorylation and ameliorated ALI histopathology(43), findings that align closely with our observations. The mTOR pathway has also been implicated in ALI pathobiology; salidroside attenuated lung damage by curtailing mTOR phosphorylation in rat models of endotoxin shock(44). Regarding VEGF signalling, earlier work suggests a contextual, time-dependent role: early VEGF release increases pulmonary vascular permeability, whereas sustained depletion of VEGF/VEGFR-1 compromises alveolar epithelial viability(45). Conversely, activation of macrophage-specific VEGF-C/VEGFR-3 signalling ameliorated LPS-induced ALI by enhancing resolution of alveolar inflammation(46). Collectively, these data implicate salidroside-mediated fine-tuning of MAPK, mTOR and VEGF networks as a central mechanism underlying its protective effects against ALI.\u003c/p\u003e\n\u003cp\u003eMolecular docking results revealed that Sal exhibited favorable binding affinities to MAPK14 (p38MAPK) and GPX4, with binding energies of -6.7 and -6.4 kcal/mol, respectively. This suggests that Sal may exert therapeutic effects on ALI by modulating these two target genes. Yang et al.(47)demonstrated that in an LPS-induced ALI model, phosphorylation levels of p38MAPK were significantly elevated, and inhibition of p38MAPK phosphorylation markedly alleviated ALI symptoms. Similarly, Zhang et al.(48)reported that in pediatric sepsis-induced ALI, overexpression of MAPK14 enhanced oxidative stress, lipid peroxidation, iron accumulation, promoted neutrophil infiltration, and upregulated PD-L1 expression, leading to immunosuppression. Knockdown of MAPK14 reduced ferroptosis and attenuated ALI, which is consistent with our findings. Furthermore, Wu et al.(49)identified MAPK14 as a hub gene potentially playing a critical role in the inflammatory regulation of ALI through bioinformatic analysis. Numerous studies have also indicated that phosphorylated p38MAPK levels are significantly increased in ALI, and inhibition of its phosphorylation via traditional Chinese medicine substantially alleviated ALI symptoms(50, 51). As a key marker of ferroptosis(52), GPX4 expression was found to be significantly reduced in ALI, promoting ferroptotic cell death. Treatment with herbal medicine was shown to upregulate GPX4 levels, suppress ferroptosis, and consequently ameliorate ALI(53-55).\u003c/p\u003e\n\u003cp\u003eThe present study demonstrated that Sal effectively reduced the expression levels of IL-6 and ROS in ALI. Wu et al.(56)reported that during sepsis, pulmonary capillary endothelial cells stimulated by cytokines such as IL-1, IL-6, and TNF-\u0026alpha; exhibit increased vascular permeability, leading to the leakage of plasma components (including water and proteins) into the alveolar space and resulting in pulmonary edema. Inhibition of IL-6 expression has been shown to alleviate ALI(57-59). Additionally, in ALI, excessive ROS production damages pulmonary vascular endothelial cells, promotes fluid leakage, and exacerbates lung injury(60). Suppression of ROS generation has been found to reverse ALI symptoms(61-63). These findings are consistent with our results, indicating that reduction in IL-6 and ROS levels can lead to the amelioration of ALI. Nevertheless, this study has certain limitations. Future investigations will focus on the following aspects:(1) Examining downstream proteins of MAPK signaling and other proteins associated with ferroptosis; (2) Establishing in vivo models to validate whether Sal mitigates acute lung injury through this pathway.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eIn summary, Sal was identified through network pharmacology and molecular docking as a promising active compound for the treatment of ALI. Preliminary in vitro experiments demonstrated that Sal pretreatment attenuates inflammatory response and oxidative stress, thereby conferring protection to lung tissue, likely via modulation of the MAPK/GPX4 signaling pathway (Fig.\u0026nbsp;14). These findings suggest that salidroside may serve as a potential therapeutic agent against LPS-induced ALI.\u003c/p\u003e\u003cp\u003e\u003cb\u003eFigure 14. Schematic of the protective mechanism of Sal against LPS-induced ALI. Sal inhibits the IL-6-gp130 interaction, thereby suppressing the MAPK/GPX4 pathway. This leads to the downregulation of ROS, MDA, and Fe\u0026sup2;⁺, ultimately inhibiting ferroptosis in alveolar epithelial cells.\u003c/b\u003e\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 114px;\"\u003e\n \u003cp\u003eSal\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 454px;\"\u003e\n \u003cp\u003eSalidroside\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 114px;\"\u003e\n \u003cp\u003eALI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 454px;\"\u003e\n \u003cp\u003eAcute lung injury\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 114px;\"\u003e\n \u003cp\u003eGO\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 454px;\"\u003e\n \u003cp\u003egene ontology\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 114px;\"\u003e\n \u003cp\u003eIL-6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 454px;\"\u003e\n \u003cp\u003eInterleukin-6\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 114px;\"\u003e\n \u003cp\u003eKEGG\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 454px;\"\u003e\n \u003cp\u003eKyoto Encyclopedia of Genes and Genomes\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 114px;\"\u003e\n \u003cp\u003eLPS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 454px;\"\u003e\n \u003cp\u003eLipopolysaccharide\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 114px;\"\u003e\n \u003cp\u003eARDS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 454px;\"\u003e\n \u003cp\u003eAcute Respiratory Distress Syndrome\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 114px;\"\u003e\n \u003cp\u003eLPO\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 454px;\"\u003e\n \u003cp\u003eLipid peroxides\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 114px;\"\u003e\n \u003cp\u003eMDA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 454px;\"\u003e\n \u003cp\u003eMalondialdehyde\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 114px;\"\u003e\n \u003cp\u003eIL-1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 454px;\"\u003e\n \u003cp\u003eInterleukin-1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 114px;\"\u003e\n \u003cp\u003eGPX4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 454px;\"\u003e\n \u003cp\u003eGlutathione Peroxidase 4\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 114px;\"\u003e\n \u003cp\u003eCCK8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 454px;\"\u003e\n \u003cp\u003eCell Counting Kit-8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 114px;\"\u003e\n \u003cp\u003emTOR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 454px;\"\u003e\n \u003cp\u003eMammalian target of rapamycin\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 114px;\"\u003e\n \u003cp\u003eTNF-\u0026alpha;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 454px;\"\u003e\n \u003cp\u003eTumor Necrosis Factor-\u0026alpha;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 114px;\"\u003e\n \u003cp\u003eVEGF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 454px;\"\u003e\n \u003cp\u003eVascular endothelial growth factor\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 114px;\"\u003e\n \u003cp\u003eROS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 454px;\"\u003e\n \u003cp\u003eReactive oxygen species\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe want to acknowledge the support of our institution and resources.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was funded by the National Natural Science Foundation of China (82471061), Shandong Natural Science Foundation (ZR2023MH035), and Youth Science Foundation Cultivation Support Program (Natural Science) of Shandong First Medical University \u0026amp;Shandong Academy of Medical Sciences (202201-009).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCRediT authorship contribution statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMin Zhao: Software, Validation, Formal analysis, Writing\u0026mdash;review \u0026amp; editing. Min Zhao and Meng Qi Wang: Conceptualization, Writing\u0026mdash;original draft. Wei Fang and Man Chen: Conceptualization, Investigation, Supervision and Editing. Wei Lin: Supervision, Writing\u0026mdash;review \u0026amp; editing.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData availability\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe Data is provided within the manuscript or supplementary information files.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eMeyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome. Lancet. 2021;2021(1/1):622\u0026ndash;37.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSilva JD, Su Y, Calfee CS, Delucchi KL, Weiss D, McAuley DF et al. Mesenchymal stromal cell extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS. EUR RESPIR J. 2021 2021/1/1;58(1).\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMatthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, et al. Acute respiratory distress syndrome. NAT REV DIS PRIMERS. 2019;2019/1/1(1):18.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKhan G, Sheek-Hussein M, Al Suwaidi AR, Idris K, Abu-Zidan FM. Novel coronavirus pandemic: A global health threat. TURK J EMERG MED. 2020;2020/1(120):55\u0026ndash;62.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVaninov N. In the eye of the COVID-19 cytokine storm. NAT REV IMMUNOL. 2020;2020(1/1):277.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eTisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. MICROBIOL MOL BIOL R. 2012;2012/1(1):16\u0026ndash;32.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLi D, Ren W, Jiang Z, Zhu L. Regulation of the NLRP3 inflammasome and macrophage pyroptosis by the p38 MAPK signaling pathway in a mouse model of acute lung injury. MOL MED REP. 2018;2018/1(1):4399\u0026ndash;409.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHou L, Yang Z, Wang Z, Zhang X, Zhao Y, Yang H, et al. NLRP3/ASC-mediated alveolar macrophage pyroptosis enhances HMGB1 secretion in acute lung injury induced by cardiopulmonary bypass. LAB INVEST. 2018;2018(1/1):1052\u0026ndash;64.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDahao L, Ju G. Research progress on the role of cell pyroptosis in sepsis induced acute lung injury. J Clin Anesthesiology. 2024;2024(1/1):412\u0026ndash;5.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLiu P, Feng Y, Li H, Chen X, Wang G, Xu S, et al. Ferrostatin-1 alleviates lipopolysaccharide-induced acute lung injury via inhibiting ferroptosis. CELL MOL BIOL LETT. 2020;2020/1(1):10.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eQiang Z, Dong H, Xia Y, Chai D, Hu R, Jiang H. Nrf2 and STAT3 alleviates ferroptosis-mediated IIR‐ALI by regulating SLC7A11. OXID MED CELL LONGEV. 2020 2020/1/1;2020(1):5146982.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGuo D, Cai S, Deng L, Xu W, Fu S, Lin Y et al. Ferroptosis in pulmonary disease and lung cancer: molecular mechanisms, crosstalk regulation, and therapeutic strategies. MEDCOMM. 2025 2025/1/1;6(3):e70116.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;2012/1(1):1060\u0026ndash;72.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eTang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. CELL RES. 2019;2019(1/1):347\u0026ndash;64.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGhio AJ, Carter JD, Richards JH, Richer LD, Grissom CK, Elstad MR. Iron and iron-related proteins in the lower respiratory tract of patients with acute respiratory distress syndrome. CRIT CARE MED. 2003;2003/1(1):395\u0026ndash;400.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWenyu W, Nuoran L, Kai W, Xin J, Wanning L, Yunsheng X et al. Research progress and exploration of traditional Chinese medicine inhibiting cell pyroptosis in the treatment of sepsis induced acute lung injury. Chin J Chin Mater Med. 2025:1\u0026ndash;13.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYiju L, Dengjun J. Research progress on traditional Chinese medicine compound therapy for acute lung injury based on NF - κ B signaling pathway. Hunan J Traditional Chin Med. 2025;41(01):171\u0026ndash;4.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChenfei F, Qun L, Jianlong L. Research progress on the treatment of sepsis induced acute lung injury with traditional Chinese medicine monomers. J changchun Univ traditional Chin Med. 2024;40(02):219\u0026ndash;25.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHou Y, Fan F, Xie N, Zhang Y, Wang X, Meng X. Rhodiola crenulata alleviates hypobaric hypoxia-induced brain injury by maintaining BBB integrity and balancing energy metabolism dysfunction. Phytomedicine. 2024 2024/1/1;128:155529.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMu L, Wang G, Yang X, Liang J, Tong H, Li L et al. Physiological premature aging of ovarian blood vessels leads to decline in fertility in middle-aged mice. NAT COMMUN. 2025 2025/1/1;16(1):72.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHuang G, Cai Y, Ren M, Zhang X, Fu Y, Cheng R, et al. Salidroside sensitizes Triple-negative breast cancer to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy. J ADV RES. 2025;2025/1(/1):74:589\u0026ndash;607.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eShuyi N, Zhao J, Zhongtao W, Shumei H. The effect of salidroside on the immune function of macrophages infected with BCG vaccine. J Shanghai Jiao Tong Univ (Medical Edition). 2025;2025(1/1):426.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSong D, Zhao M, Feng L, Wang P, Li Y, Li W. Salidroside attenuates acute lung injury via inhibition of inflammatory cytokine production. BIOMED PHARMACOTHER. 2021 2021/1/1;142:111949.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZhang P, Zhang D, Zhou W, Wang L, Wang B, Zhang T, et al. Network pharmacology: towards the artificial intelligence-based precision traditional Chinese medicine. BRIEF BIOINFORM. 2024;2024/1(1):bbad518.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRudrapal M, Chetia D. Virtual screening, molecular docking and QSAR studies in drug discovery and development programme. J drug delivery Ther. 2020;2020/1(1):225\u0026ndash;33.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKim S, Chen J, Cheng T, Gindulyte A, He J, He S et al. PubChem 2025 update. NUCLEIC ACIDS RES. 2025 2025/1/1;53(D1):D1516\u0026ndash;25.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. NUCLEIC ACIDS RES. [Journal Article; Research Support, Non-U.S. Gov't]. 2014 2014/7/1;42(Web Server issue):W32\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMendez D, Gaulton A, Bento AP, Chambers J, De Veij M, F\u0026eacute;lix E, et al. ChEMBL: towards direct deposition of bioassay data. NUCLEIC ACIDS RES. 2019;2019(1/147D1):D930\u0026ndash;40.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDeng J, Wei L, Chen Y, Li X, Zhang H, Wei X, et al. Identification of benzo (a) pyrene-related toxicological targets and their role in chronic obstructive pulmonary disease pathogenesis: a comprehensive bioinformatics and machine learning approach. BMC Pharmacol Toxicol. 2025;2025/1(1):33.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eU C. UniProt: the Universal Protein Knowledgebase in 2025. NUCLEIC ACIDS RES. [Journal Article]. 2025 2025/1/6;53(D1):D609\u0026ndash;17.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSafran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M et al. GeneCards Version 3: the human gene integrator. DATABASE-OXFORD. [Journal Article; Research Support, Non-U.S. Gov't]. 2010 2010/8/5;2010:baq20.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAmberger JS, Hamosh A. Searching online mendelian inheritance in man (OMIM): a knowledgebase of human genes and genetic phenotypes. Curr protocols Bioinf. 2017;2017/1/(1):1\u0026ndash;2.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDavis AP, Wiegers TC, Sciaky D, Barkalow F, Strong M, Wyatt B et al. Comparative toxicogenomics database\u0026rsquo;s 20th anniversary: update 2025. NUCLEIC ACIDS RES. 2025 2025/1/1;53(D1):D1328-34.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSzklarczyk D, Nastou K, Koutrouli M, Kirsch R, Mehryary F, Hachilif R et al. The STRING database in 2025: protein networks with directionality of regulation. NUCLEIC ACIDS RES [Journal Article]. 2025 2025/1/6;53(D1):D730\u0026ndash;7.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDennis GJ, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. GENOME BIOL. [Journal Article; Research Support, U.S. Gov't, P.H.S.]. 2003 2003/1/20;4(5):P3.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHuppert LA, Matthay MA, Ware LB. Pathogenesis of acute respiratory distress syndrome. Thieme Med Publishers. 2019 2019/1/1;40:31\u0026thinsp;\u0026ndash;\u0026thinsp;9.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eReilly JP, Calfee CS, Christie JD. Acute respiratory distress syndrome phenotypes. Thieme Med Publishers. 2019;2019/1(/1):40:19\u0026ndash;30.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGhasemzadeh Rahbardar M, Razavi BM, Naraki K, Hosseinzadeh H. Therapeutic effects of minocycline on oleic acid-induced acute respiratory distress syndrome (ARDS) in rats. Naunyn-schmiedeberg's Archives of Pharmacology. 2023 2023/1/1;396(11):3233\u0026ndash;42.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZhao M, Lv G, Huang X, Niu Y, Zhang Q, Li W. Mechanism and Experimental Verification of Rhodiola rosea L. for the Treatment of Acute Lung Injury Through Network Pharmacology and Molecular Docking. NAT PROD COMMUN. 2024;2024(1/1):1934578X241245550.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAngang L, Xiao L, Junmei L, Cong P, Jianxun L. Research progress on traditional Chinese medicine regulating oxidative stress and intervening in acute lung injury. Chin J Experimental Traditional Med Formulae. 2025;31(10):305\u0026ndash;12.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGuo B, Zuo Z, Di X, Huang Y, Gong G, Xu B, et al. Salidroside attenuates HALI via IL-17A-mediated ferroptosis of alveolar epithelial cells by regulating Act1-TRAF6-p38 MAPK pathway. CELL COMMUN SIGNAL. 2022;2022/1(1):183.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHaoting M, Guanglan X, Mei Z, Wenjiao Y, Guangyao W, Dan Y, et al. Research progress on the protective effect of salidroside on acute lung injury. Chin Archives Traditional Chin Med. 2021;39(05):130\u0026ndash;2.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChangci T, Yunen L, Hongxu J, Yubiao Z, Shilin, Mingxiao H, et al. Study on the protective mechanism of salidroside against lipopolysaccharide induced acute lung injury. J Clin Emerg Med. 2015;16(09):667\u0026ndash;71.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYunying X. Exploring the role and mechanism of salidroside in regulating acute lung injury through the PI3K Akt mTOR pathway. Chengdu University of Traditional Chinese Medicine; 2024.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMura M, Han B, Andrade C, Seth R, Hwang D, Waddell TK, et al. The early responses of VEGF and its receptors during acute lung injury: implication of VEGF in alveolar epithelial cell survival. CRIT CARE. 2006;2006(1/1):R130.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYamashita M, Niisato M, Kawasaki Y, Karaman S, Robciuc MR, Shibata Y et al. VEGF-C/VEGFR-3 signalling in macrophages ameliorates acute lung injury. EUR RESPIR J. 2022 2022/1/1;59(4).\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYali Y, Rong T, Yin Y, Yanjia W, Xiaoling Y. The role of FoxO1/p38 MAPK signaling pathway in LPS induced acute lung injury. Chin Pharmacol Bull. 2023;39(01):36\u0026ndash;42.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZhang N, Fan Y, Chen J, Gu J, Yan X. MAPK14 drives Ferroptosis and immune dysfunction in pediatric Sepsis-induced acute lung injury. CELL IMMUNOL. 2025 2025/1/1;411:104948.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSiyang W, Xia H, Pinhu L. Potential diagnostic biomarkers and Mapk14 protein expression: Autophagy-related genes linking immune infiltration in acute respiratory distress syndrome. INT J BIOL MACROMOL. 2024 2024/1/1;279:135077.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZhai Y, Chen K, Xu Z, Chen X, Tong J, He Y, et al. Harmine alleviates LPS-induced acute lung injury by inhibiting CSF3-mediated MAPK/NF-κB signaling pathway. RESP RES. 2025;2025/1(1):1\u0026ndash;16.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWang Y, Mou C, Huang L, Su J, You L, Zhang J et al. The ethanolic extract of Rhaphidophora peepla prevents inflammation by inhibiting the activation of Syk/AKT/NF-κB and TAK1/MAPK/AP-1. PHYTOMEDICINE. 2025 2025/1/1;136:156339.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFeng C, Yong Z, Xiang W, Jintao D, Zhihao W. Research progress on the role and mechanism of glutathione peroxidase GPX4 in ferroptosis. J Mod Oncol. 2021;29(07):1254\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eJing L, Jun P, Jing Z, Yun W, Xinyi L. The mechanism of irisin alleviating lipopolysaccharide induced acute lung injury in rats through the Nrf2/GPX4 signaling pathway. New Med Knowl. 2023;33(02):83\u0026ndash;90.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLi J, Deng S, Li J, Li L, Zhang F, Zou Y, et al. Obacunone alleviates ferroptosis during lipopolysaccharide-induced acute lung injury by upregulating Nrf2-dependent antioxidant responses. CELL MOL BIOL LETT. 2022;2022/1(1):29.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChen H, Xie W, Peng Z, Liu Y, Li H, Huang W. Nobiletin ameliorates heatstroke-induced acute lung injury by inhibiting ferroptosis via p53/SLC7A11 pathway. SHOCK. 2024;2024/1(1):105\u0026ndash;11.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWu C, Li H, Zhang P, Tian C, Luo J, Zhang W, et al. Lymphatic flow: a potential target in sepsis-associated acute lung injury. J INFLAMM RES. 2020;2020/1/1:961\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYan L, Lei X, Yuzhu S, Xue W. Exploring the protective mechanism of Artemisia annua extract on acute lung injury mice based on NLRP3 inflammatory pathway. CHIN HERB MED. 2025;56(16):5837\u0026ndash;46.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZhang J, Zhang M, Huo X, Ning J, Yu Z, Morisseau C, et al. Macrophage inactivation by small molecule wedelolactone via targeting sEH for the treatment of LPS-induced acute lung injury. ACS Cent SCI. 2023;2023/1(1):440\u0026ndash;56.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYe Y, Xie M, Nie H, Zhang G, Tu L, Ao M, et al. Investigation of the Effect and Mechanism of Fei Re Pu Qing Powder in Treating Acute Lung Injury (ALI) by Modulating Macrophage Polarization via Serum Pharmacology and Network Pharmacology. J ETHNOPHARMACOL. 2025;2025/1/1:120089.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYing H, Dandan H. Research progress on the correlation between endoplasmic reticulum stress and exacerbation of acute lung injury. J Sun Yat sen Univ (Medical Sci Edition). 2025;46(04):568\u0026ndash;73.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZhai Z, Ouyang W, Yao Y, Zhang Y, Zhang H, Xu F et al. Dexamethasone-loaded ROS-responsive poly (thioketal) nanoparticles suppress inflammation and oxidative stress of acute lung injury. Bioactive Mater. 2022 2022/1/1;14:430\u0026thinsp;\u0026ndash;\u0026thinsp;42.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMuhammad W, Liang M, Wang B, Xie J, Ahmed W, Gao C. NAC-grafted ROS-scavenging polymer nanoparticles for modulation of acute lung injury microenvironment in vivo. Biomacromolecules. 2024;2024(1/1):528\u0026ndash;40.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLuo Z, Wang Q, Fan X, Koh XQ, Loh XJ, Wu C, et al. ROS-Driven Nanoventilator for MRSA‐Induced Acute Lung Injury Treatment via In Situ Oxygen Supply, Anti‐Inflammation and Immunomodulation. ADV SCI. 2025;2025(1/1):2406060.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"respiratory-research","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"rere","sideBox":"Learn more about [Respiratory Research](http://respiratory-research.biomedcentral.com/)","snPcode":"12931","submissionUrl":"https://submission.nature.com/new-submission/12931/3","title":"Respiratory Research","twitterHandle":"@RespiratoryBMC","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Network pharmacology, Salidroside, Acute lung injury, Molecular mechanism, Ferroptosis","lastPublishedDoi":"10.21203/rs.3.rs-7610425/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7610425/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eObjective\u003c/h2\u003e\u003cp\u003eThis study aimed to combine network pharmacology with in vitro experiments to identify the key targets and potential mechanisms of salidroside (Sal) in the treatment of acute lung injury (ALI).\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e\u003cp\u003ePotential targets related to Sal and ALI were retrieved from the ChEMBL, SuperPRED, SwissTargetPrediction, GeneCards, OMIM, and CTD databases. Overlapping targets were imported into the STRING database and Cytoscape software to construct a protein-protein interaction (PPI) network and identify core targets. Functional enrichment analysis of these core genes, including GO and KEGG pathways, was performed using the DAVID database. Two genes, MAPK14 and GPX4, directly relevant to subsequent validation, were selected for molecular docking analysis. Furthermore, an in vitro model of ALI was established using LPS-induced alveolar type II epithelial cells to verify the protective mechanism of Sal.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e\u003cp\u003eA total of 355 potential targets associated with Sal in ALI treatment were identified. In vitro experiments showed that, compared to the LPS group, the Sal group exhibited significantly reduced secretion of IL-6, ROS, p-MAPK, MDA, and Fe\u0026sup2;⁺, along with increased GPX4 expression and attenuated lung injury.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e\u003cp\u003eIntegrated network pharmacology and experimental validation suggest that Sal pretreatment alleviates inflammatory response and oxidative stress, likely through regulation of the MAPK/GPX4 signaling pathway, thereby providing protection against lung tissue injury.\u003c/p\u003e","manuscriptTitle":"Combining Network Pharmacology and Experimental Validation to Demonstrate That Salidroside Alleviates Acute Lung Injury by Inhibiting Ferroptosis via the MAPK/GPX4 Pathway","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-10-21 13:02:39","doi":"10.21203/rs.3.rs-7610425/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-12-30T18:47:05+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-11-10T18:12:23+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"306224453857414500961806840893296852374","date":"2025-10-28T14:19:03+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"291582414055283137478850037903635406881","date":"2025-10-10T13:54:19+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-10-08T13:10:24+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-09-18T18:04:51+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-09-18T08:41:45+00:00","index":"","fulltext":""},{"type":"submitted","content":"Respiratory Research","date":"2025-09-14T04:34:43+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"respiratory-research","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"rere","sideBox":"Learn more about [Respiratory Research](http://respiratory-research.biomedcentral.com/)","snPcode":"12931","submissionUrl":"https://submission.nature.com/new-submission/12931/3","title":"Respiratory Research","twitterHandle":"@RespiratoryBMC","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"f8966350-8710-4372-a6d3-140559dd4dc4","owner":[],"postedDate":"October 21st, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2026-02-09T16:02:01+00:00","versionOfRecord":{"articleIdentity":"rs-7610425","link":"https://doi.org/10.1186/s12931-026-03529-1","journal":{"identity":"respiratory-research","isVorOnly":false,"title":"Respiratory Research"},"publishedOn":"2026-02-04 15:57:38","publishedOnDateReadable":"February 4th, 2026"},"versionCreatedAt":"2025-10-21 13:02:39","video":"","vorDoi":"10.1186/s12931-026-03529-1","vorDoiUrl":"https://doi.org/10.1186/s12931-026-03529-1","workflowStages":[]},"version":"v1","identity":"rs-7610425","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7610425","identity":"rs-7610425","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}